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ABSTRACT 
 
 
SRITAMA NATH. Transcriptional regulation of genes associated with drug resistance 
and growth of pancreatic cancer cells by Mucin1 (Under the direction of DR. PINKU 
MUKHERJEE) 
 
 
Pancreatic ductal adenocarcinoma (PDA) is the 4th leading cause of cancer-related 
deaths in the US. An understanding of the molecular pathogenesis of PDA is of utmost 
importance to be able to improve the current or design new targeted therapies for 
treatment of PDA. MUC1 (CD227), a membrane tethered mucin glycoprotein is 
overexpressed in >60% of human pancreatic cancers and 80% of PDA and is associated 
with poor prognosis, enhanced metastasis, and chemoresistance in PDA. The objective of 
thesis was to delineate the mechanism by which MUC1 induces drug resistance, and 
promotes invasion and proliferation in PDA.   
We report here for the first time that MUC1 contributes o drug resistance in 
pancreatic cancer (PC) via upregulating the expression of ABC transporters that reduces 
intracellular drug concentration inside the cancer cells. We found that MUC1 high PC 
cells exhibit increased resistance to chemotherapeutic drugs (gemcitabine and etoposide) 
in comparison to cells that express low levels of MUC1. This chemo resistance is 
attributed to the enhanced expression of multidrug resistance (MDR) genes including 
ABCC1, ABCC3, ABCC5 and ABCB1. In particular, levels of MRP1 protein, encoded by 
the ABCC1 gene is significantly higher in the MUC1-high PDA cells. In human PDA cell 
lines, MUC1 upregulates MRP1 via an Akt dependent pathway, whereas, in mouse cells, 
MUC1 mediated MRP1 upregulation is via an Akt independent mechanism. However, in 
both mouse and human cell lines, the cytoplasmic tail motif of MUC1 associates directly 
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with the promoter region of the Abcc1/ABCC1 gene, indicating a possible role of MUC1 
as a transcriptional regulator of this gene. This is the first report to show that MUC1 can 
directly regulate the expression of MDR genes in PDA cells and thus confer drug 
resistance. 
 We also report that human and mouse PDA cell lines expressing high levels of 
endogenous MUC1 also express high levels of Cox-2 compared to MUC1 null cells. 
Further, in both mouse and human cell lines, MUC1 upregulates expression of Cox-
2/COX-2 gene via an NF-kB dependent mechanism. In MUC1 positive PDA cell lines, 
MUC1 and NF-kB binds to the 5‟UTR of Cox-2/COX-2 gene around the NFkB response 
element (within 500bp upstream of TSS), which is not observed in MUC1 null PDA 
cells. The increased expression of Cox-2 gives the MUC1 positive PDA cell lines a 
growth and/or invasive advantage.  
Lastly, we report that MUC1 modulates TGF-β signaling axis causing TGF-β1 to act as a 
tumor promoter in MUC1 high cells and acting as a tumor suppressor in MUC1 null cells. 
The difference in TGF-β1 functioning could be partly attributed to difference in the 
expression profile of the TGF-βRI and TGF-βRII and activation of the downstream 
signaling cascades.  
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CHAPTER1: INTRODUCTION 
 
 
1.1. Pancreas Structure and Function 
Pancreas is a glandular organ which is located deep within the abdominal cavity, 
just below the stomach. Anatomically it is divided broadly into three regions – head, 
body and tail of pancreas. The head of the pancreas is situated close to the duodenum, the 
centrally located large body is located just below the stomach and the tail portion is 
located furthest from the duodenum (Figure 1.1). It is a unique organ, as it has both 
exocrine and endocrine glandular functions. The exocrine part of pancreas is made up of 
acinar cells, which secretes digestive enzymes which assist in the breakdown of 
carbohydrates, proteins, and lipids. The endocrine part of the pancreas is composed of 
cell clusters called the islet of Langerhans, which secrets hormones related to 
metabolism. The islet of Langerhans is made up of four main types of cells, alpha, beta, 
gamma (PP) and delta cells. Each of these cell types performs distinct functions.  The α 
cells secrete glucagon, the β cells secrete insulin, the delta cells secrete somatostatin and 
the PP cells secrete pancreatic polypeptide, all of which are important in glucose 
metabolism and regulating blood glucose concentration.  
The digestive enzymes and hormones secreted by pancreas are transported via the 
pancreatic duct, which either empties into bile duct to form the common bile duct or 
directly empties into the duodenum. The pancreatic ducts are lined by ductal epithelial 
cells which open into sac-like-structures of acinar cells (Figure 1.2).  
2 
 
 
1.2. Pancreatic Cancer  
Pancreatic Cancer (PC) is a debilitating disease and is the fourth leading cause of 
cancer related deaths in the United States. According to SEER cancer statistics review, in 
2013, an estimated 45,220 men and women will be diagnosed with pancreatic ancer and 
an estimated 38,460 patients will  die from the disease [1], [2]. Both men and women are 
equally affected by this disease. The 5 year survival rate is around 3% and the median 
survival rate is less than 6 months [3], [4]. Despite tremendous advancement in the field 
of medicine and biological sciences, the mortality rate of pancreatic cancer has improved 
marginally over the last 40 years. This indicates that a better understanding of the 
incidence and progression of pancreatic cancer is much needed in order to help fight the 
disease. 
1.3. Pancreatic Ductal Adenocarcinoma (PDA) Cellular Origin and Genetic Mutations 
    Greater than 95% of pancreatic cancers arise in the epithelial ductal cells of the 
pancreas and is designated pancreatic ductal adenocarcinoma (PDA). PDA is the most 
common type of pancreatic cancer and investigators use the t rm pancreatic cancer and 
PDA synonymously.  It is commonly believed that PDA arises from genetic mutations in 
the ductal epithelial cells that line the pancreatic ducts (Figure 1.2) [3], [5]. However, 
there is evidence which suggests that transdifferentiated acinar cells may also contribute 
to PDA. The genetic mutation in K-ras is believed to be the „early‟ oncogenic event that 
leads to the initiation and development of PDA. In addition , amplification of HER-2/Neu 
gene is observed in 16% of PDA patients and  9% of PDA patients are born with 
germline mutation in BRCA2 gene [6], [7]. As the disease progresses, the lesions in the 
duct accumulate more genetic mutations – uch as alterations in p16, p53 and DPC4 
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genes [3] [5]. However, it is still not clear how these signature genetic mutations 
contribute to the initiation or the progression of the disease. Global genomic analysis on 
24 pancreatic cancer samples indicated that the great majority of PDA cells carry on an 
average 63 genetic alterations, which  causes dysregulation of a set of 12 core signaling 
pathways (Table 1.1, Fig 1.3.) [8]. 
1.4. Progression of PDA 
 Based on the pathological studies and genetic analysis of the lesions, three 
different preneoplastic lesions of the duct have been id t fied that acts as precursors of 
PDA. These lesions are pancreatic intraepithelial neoplasia (PanIN), intraductal papillary 
mucinous neoplasm (IPMN) and mucinous cystic neoplasm (MCN). Among these 
lesions, the PanIN lesions are most frequent and contribute to 85% of PDA. Another less 
frequent form of pancreatic cancer is endocrine carcinoma (PECA) or endocrine tumors 
which accounts for less than 2% of pancreatic malignancies. PanINs are graded into four 
categories based on the severity of dysplasia (1A, 1B, 2, and 3). In majority of cases, 
low-grade PanINs (PanINs-1A, PanINs-1B, PanINs-2) may be found in individuals 
without any clinical manifestation of the disease. In cotrast, PanINs-3 (also referred to 
as in-situ carcinoma) [9] is very rarely seen in the pancreas of individuals without PDA 
(Figure 1.4). The normal ductal epithelial cells have  cuboidal appearance, are attached 
to the basement membrane and maintain polarity. In PanIN-1, cells appear elongated and 
they overexpress mucin. In PanIN-2, moderate nuclear atypia occurs and the cells lose 
polarity and detach from the basement membrane. In PanIN -3, severe nuclear atypia is 
observed and cluster of cells bud off into the lumen of ducts. In PanIN-4, invasive 
carcinoma cells start infiltrating the neighboring healthy tissue [3]. 
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1.5. Pathology of Pancreatic Cancer 
Pancreatic cancer is characterized by poorly defined edges and intense non-
neoplastic desmoplastic stroma (Figure 1.5). The dense stroma provides a niche for the 
tumor cells to proliferate and progress into invasive metasta ic cells. In addition, 
pancreatic cancer contains pancreatic stellate cells that are crucial for the formation, 
reabsorption and turnover of the stroma. Within the tumor icroenvironment, autocrine 
and paracrine secretion of growth factors such as platelet-d rived growth factor (PDGF), 
transforming growth factor β (TGF-β) and cytokines results in continuous interaction 
between the stromal and the cancer cells. In response t  growth factors, the pancreatic 
stellate cells produce collagen fibers that form the dense stroma. Another salient feature 
of pancreatic cancer is poor vascularization which leads to tumor hypoxia. The role of 
angiogenesis in pancreatic cancer remains controversial. Although early data suggested 
that pancreatic cancer is angiogenesis-dependent, as are most solid tumors, treatment 
with inhibitors of angiogenesis has failed in patients with pancreatic cancer. Due to its 
dense stroma and low vascularization, pancreatic cancer is r sistant to most conventional 
cancer therapies. However, a recent study in a mouse model showed that targeting the 
stromal hedgehog pathway increases tumor vascularization, resulting in increased 
delivery of chemotherapeutic agents to pancreatic tumors [10]. 
1.6. Risk Factors Associated with Pancreatic Cancer 
Pancreatic cancer rarely occurs before the age of 40 [3]. In year 2006 - 2010, 
2.1% of the patients diagnosed with pancreatic cancer were in the age group of 35 to 44 
years, whereas, 26% of the pancreatic cancer patients belonged to the age group of 55 to 
64 years. The majority of the cancer patients were of 65 years age and above. [2]. This 
data indicated that the risk of developing pancreatic cancer i reases sharply after the age 
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of 50. The average age of patients diagnosed with pancreatic cancer is 71 years of age 
[2]. Several risk factors have been identified that is thought to play a key role in the 
development of the disease. Patients with a history of chronic pancreatitis, diabetes and 
chronic cirrhosis, are at a high risk of developing pancreatic cancer. Epidemiological 
studies have linked tobacco use as a major risk factor for developing pancreatic cancer 
[5]. Tobacco users have 2.5 to 3.6% increased likelihood of developing pancreatic cancer. 
Other mild risk factors include moderate intake of alcohol, caffeine, a high fat and high 
cholesterol diet [11], [12]. The most important risk factor of pancreatic cancer is a family 
history of the disease. Individuals who had primary family members being diagnosed 
with pancreatic cancer have a 2.3 fold higher predisposition to developing this disease 
[11]. 
1.7. Symptoms, Diagnosis and Treatments 
Pancreatic cancer is one of the most lethal malignancies due to its aggressive 
growth and rapid development of distant metastases. Pancreatic cancer is usually 
asymptomatic until the disease progresses to late metastatic t ge. In metastatic 
pancreatic cancer, the disease spreads predominantly to the liver and peritoneal cavity. 
Vague abdominal discomfort, nausea, dull deep upper abdominal pain, back pain and 
weight loss are some of the common symptoms of pancreatic cancer. Rarely, tumors in 
the pancreas cause duodenal obstruction or gastrointestinal bleeding [12]. Since the 
symptoms of pancreatic cancer are similar to the symptoms of a wide array of other 
diseases, the diagnosis of pancreatic cancer is often delayed until the disease has 
progressed to late metastatic stage. The delay in diagnosis accounts for the high mortality 
rate associated with pancreatic cancer.  
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The most widely accepted pancreatic cancer marker is CA 19-9 (a carbohydrate 
antigen on mucin glycoproteins) which is routinely used for monitori g the progression 
of the disease or recurrence of the tumor. However, due to its high non-specificity, the 
use of CA 19-9 for early diagnosis of pancreatic cancer is limited in clinics. A study 
showed that use of ICAM-1and osteoprotegerin along with CA 19-9 greatly improves the 
efficacy and sensitivity of the  diagnostic test for pancreatic cancer [13]. CEA 
(carcinoembryonic antigen), CA 50, CA 242, DUPAN2, MUCIN1, MUCIN2 and 
MUC5AC, elastase 1 and Span-1 are some the markers that have added to the growing 
list of pancreatic cancer markers for their diagnostic purposes [14], [15].  
Surgery is the only curative option for treatment of pancreatic c ncer. The 2 year 
survival rate following surgery is only 20-40% and recurrence of tumor with aggressive 
phenotype occurs in 50% of the patients post-surgery [16]. However, majority of the 
pancreatic cancer patients present with grossly unresectabl  umors and only a small 
percentage of pancreatic cancer patients (5-25%) are eligibl  for surgery. Hence, 
chemotherapy is the critical component of treatment regimen in combination with 
radiotherapy [12]. With the current treatment modality the median survival ranges 
between 9 months to 10 months. For over a decade, gemcitabine is th  treatment of 
choice [17], [18]. Multiple new agents with diverse mechanisms of action, such as 
oxaliplatin, bevacizumab, cisplatin  in combination with gemcitabine have been tested in 
randomized phase III clinical trials, with no improvement in outcome[19], [20], [21], 
[22]. Erlotinib (an epidermal growth factor receptor inhibitor) is the only agent which 
given in combination with gemcitabine produced a statistically significant improvement 
of survival in comparison to gemcitabine alone [18]. As of last week, FDA approved 
Abraxane (paclitaxel bound to albumin) for the treatment of patients with late stage 
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pancreatic cancer. Patients treated with Abraxane plus gemcitabine lived on average 1.8 
months longer than patients who were treated with gemcitabine only [23].  
1.8. Mucins: Classification, Structure and Function 
Mucins are a class of modular proteins characterized by the presence of mucin 
domain (also called PTS domain) rich in proline/serine/ threonine amino acids [24]. 
Mucins are typically found on the apical surface of the glandular or luminal epithelial 
cells. They are high molecular weight proteins; composed of long peptide chain called 
„apomucin‟ which is extensively modified by O-glycosylation [25].  Based on their 
location on the cell surface, and their biochemical structure, mucins are broadly classified 
into two categories: gel forming (secreted) mucins and the membrane anchored or 
transmembrane mucins. Altogether there are 20 members in the mucin family of proteins 
(Table 1. 2)  [26].  
1.8.1. Secreted Mucins 
MUC2, MUC5AC, MUC5B, MUC6, MUC7 and MUC19 belong to the family of 
secreted mucins. The main function of the secreted mucins is to oligomerize and form 
protective mucinous gel that lubricates airways or protects the underlying epithelia from 
desiccation, changes in pH, pollutants, microbes etc [27], [28]. All secreted mucins 
contain serine/threonine rich PTS or mucin domain that is extensively O- glycosylated 
(Figure 1.6 A). It also contains von Willebrandt factor domain (vWF-D) and C-terminal 
cysteine knot domains, which allow the mucin monomers to oligomerize and form 
mucinous gel. MUC7 and MUC9 are smaller secreted mucins that neither oligomerize 
nor form gels. Most of the intestinal and airway mucins are of secreted form, with the 
exception of MUC1, which is a membrane bound mucin [29].  
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1.8.2. Membrane Bound Mucins 
MUC1, MUC3A/3B, MUC4, MUC12, MUC16, MUC17, MUC21 and MUC22 
are members of the membrane bound mucins [30]. The hallmark of membrane tethered 
mucins, is their heavily glycosylated, large extracellular domain which extends up to a 
remarkable distance 1500 nm from the cell surface [24]. The large number of 
carbohydrate side chains on the extracellular domain gives the transmembrane mucins 
their classic bottle-brush appearance.  
Membrane bound mucins are single pass, type I transmembrane proteins, which 
have plethora of biological functions ranging from acting as anti-adhesive molecule to 
signal transduction molecule. By definition, membrane bound mucins bear serine/ 
threonine rich PTS domain, Sea urchin sperm protein Enterokinase (SEA) domain, a 
membrane spanning hydrophobic transmembrane domain (TMD) and a cytoplasmic 
domain (CD) or cytoplasmic tail (CT) (Figure 1.6B). The PTS, SEA domain mainly 
comprises the extracellular domain of the membrane tether d mucin. The PTS domain is 
encoded by a large intronless and highly polymorphic gene of more than 10kb size. As a 
result the sequence and the length of this domain vary greatly among different members 
of the membrane anchored mucins. Hence, this region is also c lled as variable number 
tandem repeat (VNTR) region (Figure1.7). The polymorphism of VNTR region of the 
membrane bound mucins add a great variety to their biological role [31] [25], [29].  
VNTR region comprises of multiple copies of a sequence motif of 20 amino acids, which 
makes up the peptide core. In mature mucins large branches of sugar chains are added to 
the hydroxyl group of the serine and threonine residues of VNTR (Figure 1.6A) [24].  
The conserved SEA domain acts as a cleavage site, where mucins undergo 
autoproteolysis within GSVVV site of SEA domain. MUC1, MUC3, MUC4, MUC16 
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and MUC17 bear the conserved SEA domain [31]. The autoproteolysis can occur within 
the cytosol or outside the cell membrane. It is thought that conformational strain induces 
the autoproteolysis of mucins. Additionally studies have shown that ADAM 17 (also 
known as TACE) and MMP1 can trigger shedding of MUC1 in response to TNF 
stimulation [32].  
The cytoplasmic tail of mucins is also poorly conserved among different members 
of the membrane tethered mucins. (Table 1.3) [25]. Studies have shown that most of the 
membrane bound mucins such as MUC1, MUC3 and MUC4 have signaling ab lity, 
which mostly lies within the cytoplasmic domain (tail). The cytoplasmic tail of MUC1 
and MUC3 has been extensively studied. This will be discussed in detail under the 
section, structure of mucin 1. 
1.8.3. Glycosylation of Mucins 
Following synthesis, the apomucins are extensively modified co-translationally or 
post translationally to yield the mature functional mucins. The VNTR is mostly O-
glycosylated and to a lesser extent is N- glycosylated.  O-glycosylation status correlates 
with some biological properties of mucins, whereas, N-Glycos lation is vital for their 
folding, sorting, and secretion.  
In the sequence of addition of sugar moieties to the apomucin, N- glycosylation 
occurs first, which is a co-translational event. The mannose rich oligosaccharide is 
transferred to an acceptor asparagine residue in the tripeptide Asn-Xaa-Ser/Thr, motif on 
VNTR. The reaction is catalyzed by a number of enzymes blonging to N-
acetylgalactoseaminyltransferase (GalNAcT) family [26][33]. The mannose-rich N-
glycans undergo further modification and truncation in the Golgi apparatus [34]. About 
40% of the amino acid in the VNTR comprises of serine (Ser) and threonine (Thr) 
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residues. In the glogi apparatus, step by step O-glycosylation occurs, where Galactose, N-
acetylgalactoosamine (GalNAc), fucose, and/or sialic acid re added to the hydroxyl 
group of Ser and Thr residues of VNTR by GalNAc transferases [25], 35]. The sugar 
moieties greatly influence the overall charge, molecular weight and biological functions 
of the mucins [32]. In addition, glycosylation stabilizes mucins at the cell surface by 
preventing them from undergoing clathrin mediated endocytosis and also shields them 
from the proteolytic attack of the environmental enzymes[36][37][37] .  
The membrane anchored mucins are eventually transported from ER lumen to the 
cell surface where it undergoes a series of recycling events. During recycling of the 
mucin through the trans-Golgi network, its sialylation increases and further changes 
occur in its O-glycosylation status [38]. During transit from ER lumen to the cell surface, 
secreted mucins oligomerize through disulfide bridges and are subsequently packaged 
into secretory granules. Membrane tethered mucins, are trnsported via trans-golgi 
network to the cells surface, where they are transiently xpressed, until they are trafficked 
back to trans-golgi network to undergo further glycosylation cycles. Through the process 
of continued sialylation, the O-glycans of mucins gain maturation, as a consequence of 
which, the glycosylation pattern of secreted mucins is different from the membrane 
tethered mucins [38]. 
1.8.4. Functions of Mucins in Normal Epithelial Cells 
The mucins mainly provide physiochemical protection from several adverse 
environmental conditions. The secreted mucins form mucinous gel around the apical 
surface of the epithelial cells, which protects them from dessication, changes in pH, entry 
of microbes etc. It is also thought that mucins act as stress sensor molecules. In normal 
conditions, mucins sequester growth factors, chemokines ad inflammatory cytokines, 
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such as EGF, TGF-α, IL-1, TNF-α, IL-4, IL-6, IL-9 and IL-13.  However, during breach 
of the physicochemical barrier, release of the mucin etodomains causes release of the 
sequestered factors which now sends off warning signal by triggerin  inflammation. It is 
also thought that conformational changes or changes in the ligand status caused by the 
release of mucin ectodomain triggers activation of the signaling axis of mucins (Figure 
1.8 ) [39].   
1.9. Structure of Mucin 1 (MUC1) 
Mucin 1 (MUC1), a polymorphic, type I transmembrane glycoprotein is normally 
expressed at the apical surface of the glandular or luminal epithelial cells and to some 
lesser extent in hematopoietic cells [40][41]. MUC1 is mostly found in the pulmonary 
tracts, intestinal linings, mammary glands, pancreas and female reproductive tract. It is 
also referred to as episialin, PEM, H23Ag, EMA, CA15–3, MCA [42]. The gene 
encoding MUC1 is located on the long arm (q) of chromosome 1 at position 21, a region 
which is frequently altered in breast cancer cells [43]. The MUC1 gene is encoded as a 
single polypeptide chain. Immediately after translation, conformational stress causes 
breakage of the MUC1 polypeptide chain into two subunits of varying sizes – the longer 
N terminal and the shorter C-terminal subunits (Figure 1.9).The autoproteolysis occurs at 
GSVVV site which lies within the SEA domain between the N-terminal a d C-terminal 
subunits [24], [44] (Figure 1.10). The two subunits remain non-covalently associated 
through hydrogen bonds and are exported to the surface of thecell. The exact functional 
significance of the autoproteolysis still remains to be elucidated. It is believed that 
autoproteolysis allows rapid shedding of the extracellular domain of MUC1 in response 
to stress, which forms a protective barrier around the epithelial cells to protect the cells 
from environmental insults. 
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The N-terminal subunit of MUC1 is mainly extracellular and it comprises of PTS 
domain and SEA domain.  The 20 amino acids repeats in the VNTR vary from 40-60 in 
numbers depending upon allelic polymorphism. Unlike human MUC1, the mouse Muc1 
does not have variable number tandem repeat. The N-terminal co sists of 16 tandem 
repeats of 20-21 amino acids [45]. The serine and threonine residues of VNTR are 
extensively modified by O-glycosylation, along with moderat N- glycosylation on five 
sites C-terminal to the VNTR region [40]. Glycosylation of MUC1 occurs in the Golgi 
complex and contributes 50-90% of the total weight of the protein.  MUC1 expressed by 
different tissues have similar peptide core, but they differ n the number of tandem 
repeats and in the glycosylation pattern. Tissue specific glycosylation pattern of MUC1 
depends upon the expression profile of the glycosyltransferases in those tissues [24]. 
Thus, MUC1 can weigh between 250-500KDa based on the presence of the number of 
repeats and the extent of glycosylation. In normal epith lial cells, MUC1 is heavily 
glycosylated and the peptide core is masked by the sugar moieties. But in cancer cells, 
MUC1 is undersglycosylated, which reveals the peptide core [46]. The unmasked peptide 
backbone of tumor associated MUC1 behaves as a strong immnodo inant peptide. 
In contrast to the long N-terminal domain, the C-terminal domain of MUC1 is 
rather short. The C-terminal subunit mainly comprises of 53 amino acids long SEA 
domain, 28 amino acids long single pass transmembrane (TM)domain and 72 amino 
acids long cytoplasmic tail (CT). The N-terminal and C-terminal subunit are linked by 
non-covalent bonds at the GSVVV motif. The cytoplasmic ta l of MUC1 weighs around 
23 - 25KDa, which is further cleaved by TACE/ADAM17 or MT1/MMP  to generate a 
shorter peptide with a molecular mass of 15-17KDa (Figure 1.11) [47]. The cytoplasmic 
tail of MUC1 contains a CQC motif. MUC1 monomers associate at CQC motif to 
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generate functional homodimers, which translocates to the nucleus and participates in 
regulation of gene expression. The cytoplasmic tail of MUC1 contains phosphorylated 
tyrosine and serine residues, which acts as docking sites for certain signaling molecules 
and thus participates in cell signaling cascades (Figure 1.12). The TM domain and six of 
the seven tyrosine residues of MUC1 CT are highly conserved (88% and 100% identical 
respectively) among different species of mammals suggesting important functional roles 
[24].  Phosphorylated tyrosine 20 and tyrosine 60 of the cytoplasmic tail of MUC1 binds 
to adaptor protein complex 2 and Grb2, which facilitates clathrin mediated endocytosis of 
MUC1. Studies have shown that Cys-palmitoylation of the CQC motif is necessary for 
reentry of MUC1 in the secretory pathway [48][49]. During subsequent recycling, MUC1 
glycosylation undergoes remodeling from Core 2 to core-1O-glycan [50]. 
1.10. Alternative Splice Variants of MUC1 
In addition to full length membrane tethered MUC1; there have been undisputable 
reports about presence of MUC1 isoforms, which are preferentially expressed in tissue 
specific manner. Alternative splicing event generates truncated variants of MUC1 mRNA 
that lacks either the extracellular or cytoplasmic domain of MUC1. Till date 9 isoforms 
of MUC1 have been reported. MUC1 Y contains all the domains except the VNTR 
region [51]. It is expressed in high levels in breast, ovarian and prostate cancer cells [52], 
[53]. MUC1/X and MUC1/Z similarly lacks the VNTR region, but are 18 amino acids 
longer than MUC1/Y splice variant [40]. MUC1/SEC, which lacks the hydrophobic TM 
domain and the cytoplasmic domain, is secreted from cell and acts as a binding partner 
for MUC1/Y. Interaction of MUC1/SEC with MUC1Y results in the phosphorylation of 
tyrosine residues of MUC1/Y. Presently; there is a lack of clear understanding of the 
functional significance of the various splice variants of MUC1.  
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1.11. Expression of Mucins in Normal Pancreas and in Pancreatic Cancer 
Normal pancreatic epithelial cells express fully glycosylated form of membrane 
anchored MUC1 and secreted MUC5B. In addition, moderate expression of MUC2 and 
MUC6, and rare expression MUC5A and MUC5C are observed in these cells [9]. An 
aberrantly glycosylated form of MUC1 is overexpressed in ~ 80% of PDA (Figure1.13). 
In addition, MUC4, which is usually absent in normal pancreas, is expressed by PDA 
cells at PanIN 1 lesion and its expression gradually increases  the disease progresses. 
PanIN3 is characterized by strong expression of MUC1, MUC3 and MUC4. There are no 
reports of MUC17 expression at PanIN stage, but its overexpression is observed in 
pancreatic tumor cell lines and in tumor samples. MUC5A and MUC5C which are not 
expressed in healthy pancreas are neoexpressed in PanIN1 lesions (70% of cases) and its 
expression reaches 85% in adenocarcinoma. MUC6 expression peaks in PanIN1A (74%) 
and then decreases during carcinogenetic progression (35% of PDA). Thus, the 
expression profile of mucins alter at different stages of PDA [40]. 
Over the recent years, a large body of evidence has been gathered that indicates 
the role of membrane tethered mucins, especially MUC1, MUC4 and MUC16 in the 
progression of cancer. In clinics, MUC1 (CA15-3) and MUC16 (CA125) are used as 
biomarkers for detection of breast and ovarian cancers  [24], [54]. Among the membrane 
tethered mucins, MUC1 is the most thoroughly studied mucin in context of cancer 
progression. A clear relationship has been established between changes in the expression 
and glycosylation pattern of MUC1, and the progression of cancer; especially in breast, 
lung, colon, pancreas and prostate cancer.  
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1.12. Regulation of MUC1 Gene Expression 
Over expression of MUC1 in cancer cells is caused due to an increase in the gene 
dosage and an increase in the level of transcription of MUC1 gene [55]. Pro-
inflammatory cytokines, interferons, prolactin, steroid hormones, TNF-α and PMA 
stimulate MUC1 gene expression via activation of STAT transcription factors [56]. 
MUC1 gene promoter contains several cis-elements such as Sp1, AP1-4, NF-1, NFҡB, an 
E-box, GC boxes, and estrogen and progesterone receptor sites [40].  
1.13. Role of MUC1 in Cancer 
Research over the last decade has brought tremendous insights into the structure, 
function and role of MUC1 in the pathogenesis of cancer. Tumor associated MUC1 
differs from MUC1 expressed in normal cells, both in their biochemical features and 
cellular distribution.  In normal glandular or luminal epithelial cells, MUC1 is expressed 
at normal levels and is confined to the apical surface of the cells. But in carcinoma cells, 
MUC1 is overexpressed and loss of cell polarity causes MUC1 to be distributed all over 
the cell surface and also in the cytoplasm [40]. Lack of cell polarity in cancer cells also 
causes re-distribution of growth factors all over the cell surface, which otherwise in 
normal epithelial cells remain confined to the basal surface (Figure 1.14). Growth factors 
situated in close proximity of MUC1 phosphorylates 18 potential motifs (serine and 
tyrosine residues) on MUC1 CT and there by activates it. The phosphorylated MUC1 CT 
acts as docking site for binding other kinases and components of cell signaling cascades, 
such as Erk1/2, P13K/Akt, Wnt and are likely to regulate the activation status of these 
pathways. Hence, MUC1 positive cancer cells of pancreas, breast, lung and colon origin, 
commonly display hyperactivation of these pathways [57] [58][59][60]. In addition, 
MUC1 CT interacts with several transcription factors and redirects them to their target 
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genes. Several studies have indicated that MUC1 plays a critical role in the 
transcriptional regulation of genes that are related to invasion, metastasis, angiogenesis, 
proliferation, apoptosis, drug resistance, inflammation and immune regulation [28], [57], 
[61], [62], [63], [64], [65] [66]. Studies on mouse models of human pancreatic and breast 
cancer provides evidence that supports the importance of MUC1 in the progression of 
cancer. Muc1-/- mice expressing high levels of polyomavirus middle T antigen in the 
mammary gland spontaneously develop breast cancer, but they display a profound delay 
in the progression and metastatic spread of breast cancer to lungs in comparison to 
Muc1+/+ mice [67].  A similar study performed in a mouse model of PDA that 
spontaneously develop pancreatic cancer showed that mice null for Muc1 (KCKO) show 
delayed tumor progression and metastasis compared to mice expressing mouse 
Muc1(KC) or human MUC1(KCM) [58].  
1.13.1. Role of MUC1 in Tumor Growth 
Early studies in various tumor cell lines revealed that MUC1 plays a crucial role 
in tumor growth and survival. MUC1 induces production of growth factors such as CTGF 
and PDGF-A, PDGF-B, which promotes activation of MAPK and PI3K/Akt pathways in 
MUC1 positive cells and thereby potentiate proliferation and survival of tumor cells [58], 
[61], [68]. Upon EGF stimulation, MUC1 directly associates with EGFR, translocate to 
the nucleus and binds to the promoter of CCND1 and MYBL2 gene, which allows the 
expression of G1/S phase genes [69]. Another study showed that upon PDGF-A 
stimulation, activated MUC1 associates with HIF-1α and upregulates the expression of 
PDGF-A, leading to increased proliferation and invasion of PDA cells [63]. These 
observations are recapitulated nicely in a study on  mouse model of human PDA [58]. 
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1.13.2. Role of MUC1 in Invasion and Metastasis 
During the progression of cancer from carcinoma in-situ to metastatic disease, the 
tumor cells acquire invasive and metastatic potential. Invasion causes destruction of the 
tissues, and prevents normal organ functioning, whereas metastasis allows systemic 
dissemination of malignant cells and formation of secondary tumors. Cancer patients 
presenting locally advanced or metastatic disease are difficult to treat as surgical 
resection of tumors is not enough for cure. Thus, metastasis is the most life threatening 
aspects of cancer and accounts for 95% of death in pancreatic cancer patients [4], [70]. 
Invasion is an early and prerequisite step to metastasis. Invasion comprises of a 
cohort of biochemical events that allow the cancer cells to detach from the basement 
membrane, degrade the surrounding matrix and invade into the neighboring tissues or 
enter bloodstream [71]. Recently, a new concept emerged called EMT – epithelial to 
mesenchymal transition, to support the biological process by which cancer cells acquire 
invasive potential. In normal epithelial tissue, intracellular adhesion junctions, such as 
adherens, tight junctions and desmosomes maintain the integrity of epithelial cell layers, 
cell polarity and spatially confine the signaling molecules. Tight junctions, positioned 
apically define the segregation between the apical and basolateral surfaces of the 
epithelial cells. Whereas, adheren junctions, located directly below the tight junctions 
maintain cell to cell contact via cadherin molecules.  During EMT the junctional 
complexes are weakened, followed by loss of apico-basal pol rity and contact with 
basement membrane, finally leading to acquisition of invasive properties (Figure 1.15).   
Classical cadherin junctions constitute a basic complex formed by the association 
of cadherin molecules with α-, β- and p1β0 catenins. β-catenin bridges the gap between 
cell surface and the actin cytoskeleton through α-catenin, which gives β-catenin the 
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ability to induce changes in the cytoskeletal architecture in response to extracellular 
signals or perturbed junctional assembly [46]. In normal epithelial cells, MUC1 is 
localized to the apical surface, adheren junctions to the lateral surface and growth factors 
to the basal surface of the cells. However, stress induced loss of apico-basal polarity of 
cancer cells causes MUC1 to be redistributed all over the surface of cancer cells. As a 
result, MUC1 is found in close vicinity of adheren junctions and growth factors [24]. 
Studies have shown that the cytoplasmic tail of MUC1 associates with β-catenin, 
translocates to the nucleus and repress expression of the E-CADHERIN gene and 
upregulates expression of the EMT inducers- Snail, Slug, Vimentin and Twist [62] [72].  
As a consequence, the adheren junctions are destabilized and profound cytoskeleton 
rearrangement occurs, which makes the cancer cells to lose cell- cell contact and invade 
the basement membrane (Figure 1.9). PDGF-BB stimulation promotes nuclear 
localization of MUC1-β catenin transcriptional complex, which results in increased 
invasiveness of PDA cells [73]. Studies evaluating the relationship between MUC1 
overexpression and metastasis or prognosis on clinical samples have shown that MUC1 
overexpression leads to metastasis and poor prognosis of pancreas, gall bladder and colon 
cancer [74], [75], [76].  
After the tumor cells have left the site of primary tumor and are in circulation, the 
migrating cancer cell binds to endothelial cells, extravasate and form secondary tumors at 
distant sites. The peptide core of underglycosylated MUC1 expressed on tumor cells, acts 
as ligands to cell adhesion molecules such as I-CAM, E-selectin and SIGLECS (sialic 
acid binding immunoglobulin superfamily lectins) expressed on endothelial cells, and 
thereby aids the tumor cells to reestablish secondary tumors (Figure 1.16) [39].  
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1.13.3. Role of MUC1 in Angiogenesis 
Unregulated cellular proliferation leads to formation of cellular mass that extend 
beyond the normal vasculature. This leads to deprivation of nutrients and oxygen within 
the tumor mass. However, the proliferating tumor cells, adapt to survive amidst low 
nutrient and oxygen environment (hypoxia) by promoting formation of new blood vessels 
within the tumor. Hypoxia-inducible factor 1α (HIF-1α), an oxygen sensing molecule is 
the key mediator of cellular responses under oxidative str ss (hypoxia). HIF-1α is 
constitutively expressed and is stable for less than 5 minutes under normaxic conditions. 
The stability of HIF-1α is dependent upon the intracellular abundance of prolyl 
hydroxylase (PHD) and its activity. At normaxic conditions (O2 more than 5%), PHD 
hydroxylates HIF-1α at Pro-402 and Pro-564 and marks it for ubiquitination and 
subsequent proteosomal degradation. During oxidative stress, the elevated ROS level 
attenuates PHD activity and thereby increases stability of HIF-1α [77]. There are around 
70 genes that are under transcriptional regulation of HIF-1α [78], [79]. Activated HIF-1α 
induces expression of pro-angiogenic factors, such as vascular endothelial growth factor-
A (VEGF-A) and platelet-derived growth factor-B (PDGF-B), which promotes tube 
formation in endothelial cells and synthesis of new blood vessels within the tumor [80]. 
In addition, HIF-1α regulates the expression of enzymes involved in glycolytic pathway, 
which is the preferred metabolic pathway in   proliferating cancer cells [78].  
The signaling and transcriptional role of MUC1 is critical for mediating HIF-1α 
angiogenesis in cancer. A recent finding demonstrated that, MUC1 overexpression in 
breast cancer cells promote the synthesis and secretion of vascular endothelial growth 
factor (VEGF) through the AKT signaling pathway [81]. Recently, we showed that 
MUC1 in association with HIF-1α drives the expression of PDGF-A in PDA cells. 
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MUC1 gene itself is under regulation of HIF-1α. In pancreatic cancer and renal 
carcinoma cells, HIF-1α binds to the promoter of the MUC1 gene and drives its 
expression. MUC1 in turn drives transcriptionally upregulates th  expression of CTGF 
gene by binding to its promoter through β-catenin and p53 [64]. MUC1 induced pro-
angiogenic factors not only stimulates angiogenesis but also promotes migratory and 
invasive properties of cancer cells [63], [82], [83].  
1.13.4. Role of MUC1 in Resistance to Apoptosis 
Apoptosis or programmed cell death is a key mechanism by which p ysiological 
growth is regulated and tissue homeostasis is maintained. Most of the anti-cancer 
treatments such as chemotherapy, radiotherapy, gene th rapy and immunotherapy work 
through induction of apoptosis in cancer cells. However, most of the cancer cells have 
defects in the apoptotic pathway and therefore do not respond well to these anti-cancer 
treatments. MUC1 is one such molecule that aids cancer cells to evade cell death via 
blocking activation of intrinsic apoptotic pathway. In rat fibroblasts 3Y1, overexpression 
of MUC1 interferes with activation of apoptosis via selectively upregulating the 
expression of anti-apoptotic protein Bcl-xL and inactivating the pro-apoptotic protein 
Bad via phosphophorylating it [68]. Reactive oxygen species activates apoptotic 
pathways in hypoxic cells. However, it has been reported that MUC1 decreases 
intracellular ROS concentration by upregulating expression of catalase. Another study in 
colon cancer cell reported that MUC1 induced decrease in intracellular ROS 
concentration reduces PHD-3 activity and thereby suppress HIF-1α stability. Thus, 
MUC1 blocks hypoxia induced cell death in colon cancer cells [84].  
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Figure 1.1.Anatomical position of pancreas within the human body. [85] 
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Figure 1.2. Pancreas structure and the pancreatic cancer: (a) The pancreatic ducts empties either 
directly into the duodenum or through common bile duct. (b), (c) The pancreatic duct opens to sac 
like structures formed by acinar cells. (d) The Islets of Langerhans are found interspersed within 
acinar cells. Islets of Langerhans are made up of alpha, beta, gamma (PP) and delta cells. Figure 
adapted from [3].  
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Figure 1.3. Core signaling pathways mutated in PC: The chart displays12 core signaling 
pathways, whose component genes are genetically modified in most pancreatic cancers 
[8].  
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Table 1.1. A complete listing of the gene sets defining these signaling pathways and 
processes that are mutated [8]. 
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Figure 1.4. Progression model for pancreatic cancer: The normal pancreatic ductal 
epithelial cells undergo phenotypic changes and progresses into invasive cancer cells. 
Based on the cytological atypia of the lesions, PanINs are graded into three categories - 
PanIN 1A, PanIN 1B, PanIN 2 and PanIN 3. The signature genetic mutations that are 
commonly observed in the PanIN lesions are point mutation in K-ras gene, and 
homozygous deletion of p16, p53, DPC4 and BRCA2 genes. Figure adapted from [5]. 
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Figure 1.5. Hematoxylin and eosin staining of PanIN lesions and stromal cells in human 
PDA specimens: (a) Adenocarcinoma marked by haphazard arrangeme t of the glands 
and the associated non-neoplastic desmoplastic stroma.(b) At higher magnification - the 
desmoplastic stroma (black solid arrow) and the marked plomorphism in the cancerous 
duct [11]. 
 
 
 
 
 
(a) 
(b) 
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Table 1.2: Members of the mucin family of proteins and their cellular location. Table 
adapted from [26]. 
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Figure 1.6. Schematic representation of the general structure of mucins: A. Secreted 
mucins contain Ser/Thr rich PTS domainand cytoplasmic tail.B. All membrane anchored 
mucin containing conserved PTS domain (VNTR), EGF like domin, enterokinase, and 
agrin (SEA) domain, transmembrane domain (TMD) and cytoplasmic tail. MUC4 
exclusively contains the AMOP, NIDO and vWF domains but lacks SEA domain. The 
apoprotein is extensily O-glycosylated in both secreted and membrane anchored 
mucins[25]. 
 
 
B
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Figure 1.7. Schematic representation of the viable length of PTS domain among different 
types of human membrane bound mucins.  The PTS domain is highly polymorphic 
among the different members of the membrane bound mucins as indicated by the green 
bar. MUC4 lacks SEA domain but contains von-Williebrand (vWF-D) domain [31].   
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Table 1.3. Sequence of the cytoplasmic tail of the various members of membrane bound 
mucins: The cytoplasmic tails of membrane tethered mucins are poorly conserved. The 
size and sequence vary greatly between the various members of the mucins. The tyrosine 
residue(s) in the cytoplasmic tail of mucins is (are) phosphorylated, which acts a potential 
docking site for cell signaling molecules [47]. 
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Figure 1.8. Membrane associated mucins act as receptors or sensor  of the environment. 
(a) Membrane anchored mucins act as ligands for lectins, selectins, bacteria and other 
adhesion molecules. It also detects changes in the pH of the environment. (b) Mucin 
ectodomain is release in response to external stimuli such as changes in pH. Upon 
activation, the C-terminal subunit of mucins undergoes conformational changes, 
phosphorylation of the cytoplasmic tail and recruits signaling molecules [39]. 
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Figure 1.9. Schematic representation of the structure of MUC1: MUC1 is a heterodimer 
consisting of the N-terminal and C-terminal subunits. The N-terminal subunit comprises 
the VNTR of 20 amino acids that are extensively O-glycosylated at serine and threonine 
residues and sparingly glycosylated at the arginine residues. The C terminal domain 
consists of a 53 amino acid long extracellular domain, 28 amino acid long transmembrane 
domain and the 72 amino acid long cytoplasmic tail. Immediatly after translation, the 
MUC1 protein undergoes autoproteolysis at GVVV site to generate the N-terminal and 
C-terminal subunits. The autoproteolytic cleavage site lies with the SEA domain of the 
subunits. Figure adapted from the PhD thesis of Ashlyn Bernier. 
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Figure 1.10. Autoproteolytic cleavage of MUC1: Cleavage at the GSVVV site generates 
two subunits of MUC1 – the N-terminal and C-terminal subunits. The conformation l 
strain causes the hydroxyl group of Ser1098 to attack the carbonyl group of Gly1097. 
The two subunits are held together by hydrogen bonds. Figure has been adapted from 
[86] 
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Figure 1.11. MUC1 cleavage by sheddase: The extracellular region of MUC1 is cleaved 
by ADAM17 (TACE) or MMP1 to generate shorter peptide fragments (15-17KDa)[47] . 
 
 
 
 
Figure 1.12. Protein binding and phosphorylation sites on the cytoplasmic tail of MUC1: 
The cytoplasmic tail of MUC1 contains tyrosine (7) and serine residues that are 
phosphorylated. The phosphorylated residues physically interact with other signaling 
molecules and thus can modulate cell signaling cascades. The MUC1 monomers 
dimerizes around the CQC motif in the cytoplasmic tail Figure adapted from [47]. 
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Figure 1.13. MUC1 expression in PanIN lesions of human PDA. Immunohistochemical 
staining of MUC1 in normal pancreas and PanIN lesions using CT2 antibody which 
detects the cytoplasmic tail of MUC1. The expression of MUC1 protein increases with 
the progression of PanIN lesions. 
 
 
Figure 1.14 Loss of polarity of MUC1 in cancer cells: In normal epithelial cells, MUC1 is 
confined to the apical surface of the cells and growth factors to the basal surface. 
However, in cancer, the tumor cells lose apico-basal polrity, for which MUC1 is found 
all over the surface of the tumor cells often in close proximity of the growth factors [87]. 
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Figure 1.15. Multistep process of metastasis which occurs throug  EMT-MET transition: 
In a healthy tissue, the normal epithelial cells are attached to the basement membrane. In 
carcinoma in-situ, the transformed cells exhibit increased proliferation, loss of polarity 
followed by acquisition of invasive and metastatic properties. The cancer cells enter 
circulation, disseminate through bloodstream and exit the bloodstream at a remote site, 
where they form micro or macro metastases. Figures adapted from [71], [88]. 
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Figure 1.16. Adhesion of cancer cells via interaction of MUC1 with cell adhesion 
molecules on the endothelial cells: Tumor cells aberrantly express high levels of 
underglycosylated MUC1, exposing the peptide core, which acts as ligands for several 
cell adhesion molecules such as I-CAM, E-selectin and SIGLECS (sialic acid binding 
immunoglobulin superfamily lectins). Figure adapted from [39] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 2: MUC1 INDUCES DRUG RESISTANCE IN PANCREATIC CANCER 
CELLS VIA UPREGULATION OF MULTIDRUG RESISTANCE GENES. 
 
2.1. Introduction 
Chemoresistance: 
Chemoresistance not only affects PC but also affects various types of tumors such 
as acute myeloid leukemia (AML), ovarian, colon, pancreatic, breast and lung cancer. 
The tumor consists of mixed cell population, where some of the malignant cells are 
sensitive and some are resistant to chemotherapeutic drugs. D ring chemotherapeutic 
treatment, the drug sensitive cells are effectively eradicated, leaving behind the drug 
resistant population, which is accountable for the relapse of the disease in cancer patients.  
Drug resistance can be classified into two categories: d novo resistance or 
acquired resistance (Figure 2.1). Cancer patients that exhibit de novo resistance do not 
respond to chemotherapy from the start. However, in acquired resistance, the cancer cells 
initially respond to a chemotherapeutic drug but eventually acquire resistance to it. The 
cells might also show cross-resistance to other structurally and mechanistically unrelated 
drugs - a phenomenon commonly known as Multi Drug Resistance (MDR) [89]. Due to 
acquisition of MDR, treatment regimens that combine multiple agents with different 
targets are no longer effective [89], [90], [91]. The efficacy of chemotherapy is 
compromised in pancreatic cancer due to its inherent chemoresistant nature of the 
disease. Resistance to drugs in cancer cells is caused primarily due to two reasons: 
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Interference with the apoptotic pathway - A lot of anti-cancer drugs work through 
inducing apoptosis in cancer cells. However, most of the most cancer cells have 
deregulated apoptotic pathway and the anti-cancer drugs fail to induce apoptosis 
effectively. Thus decreased apoptosis can lead to chemoresistance.  
Efflux of drugs from the cancer cells – Another common mechanism by which cancer 
cells evade killing by drugs is via upregulation of ATP dependent membrane efflux 
pumps or ATP-binding cassette (ABC) transporters. These transporters or pumps efflux 
anticancer drugs and reduces the accumulation of drugs inside the cancer cells, thus 
allowing the cancer cells to evade the toxic effects of the drugs (Figure 2.2) [92], [93]. 
This type of resistance is mostly seen against amphipathic drugs such as vinkaalkaloids, 
anthracyclins, which enter the cell through passive diffusion. Since the movement of 
these molecules cannot be restricted, organisms starting f om bacteria to humans have 
developed methods to overcome the toxic effects of the xenobiotics by reducing their 
intracellular concentration [94].   
ABC transporters – Structure, function and expression: 
The ABC superfamily comprises of structurally and highly functionally diverse 
group of proteins that are crucial for all living cells for transport of a variety of substrates 
such as organic ions, lipids, oligosaccharide, oligopeptides, proteins, vitamins, metals etc. 
Till this date 49 ABC transporters have been identified, and they are designated A 
through G.  
The basic unit of an ABC transporter consists of four co e domains – two 
transmembrane domains (TMD) and two nucleotide binding domains (NBD) (Figure 
2.3). The hydrophobic α-helices of TMD span the plasma membrane multiple times and 
are required for the insertion of the protein into the lipid bilayer. The TMDs form 
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hydrophilic aqueous pore through which solutes are transported across the plasma 
membrane. The aqueous pore has a large opening which faces the extrac llular part of the 
membrane. In addition, TMD harbors the substrate binding site, that usually can bind a 
wide range of substrates. Table 2.1 lists the various types of ABC pumps and their 
substrates. The NBD is hydrophilic, and is peripherally situated towards the cytoplasmic 
face of the membrane. The NBD domain consists of the core 215 amino acids which bind 
ATP and use the energy of ATP catalysis to drive the export of substrates across the cell 
membrane [89], [95]. The NBD domain is highly conserved and the members of ABC 
family of proteins are defined by the presence of this domain.  
MRP1 and its structurally and functionally similar counterpart P-gp are the two 
most extensively studied ABC transporters. They share similar substrate specificity and 
they both efflux a wide variety of anticancer drugs such as etoposide, daunorubicin, 
doxorubicin, epirubicin etc. MRP1 is also called as glutathione drug conjugate pumps or 
GS-X pumps because it transports a wide range of substrates that are conjugated to 
negatively charged hydrophilic ligands such glutathione, glucuronic acid and sulfates 
[89], [94]. Structurally ABCB1 differs from P-gp around the TMD. P-gp contains two 
transmembrane domains (TMD) and two nucleotide binding domains (NBD). In contrast 
ABCC1 contains three TMD and two NBD (Figure2.4) [96] [97].  
Upregulation of Mdr1 (or ABCB1/Abcb1) gene, encodeing for P-gp and 
ABCC/Abcc (1-9) genes encoding for the MRP family of multidrug transporters are 
frequently observed in cancer cells. The increases in expression of the ABC pumps are 
thought to be responsible for increased chemoresistance in ancer cells. In particular, 
ABCB1 (P-glycoprotein), ABCC1 (MRP1), ABCC2 (MRP2) and ABCG2 (BCRP, 
MXR) actively extrude several types of anti-cancer drugs from cancer cells, thereby 
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conferring drug resistance to those agents [89].  A study involving tumors from 45 
pancreatic cancer patients was conducted to analyze the expr ssion of two types of ABC 
transporters P-gp and MRP1. It was found that 93.3% of the patints ncluded in the 
study either or expressed high levels of both P-gp and MRP1 and only a very small 
fraction of patients (6.7%) expressed neither P-gp nor MRP1[98].  In contrast, another  
study involving 31 pancreatic tumor and 6 normal pancreas samples analyzed for MRP1-
9 and BCRP expression reported that only MRP3 gene is significantly upregulated in 
pancreatic tumors and the mRNA levels match the tumor stage and grading [99].  
Analysis of human PDA cell lines BxPC3, AsPC1, PANC-1 and Capan-1 cell lines 
shows high expression of MRP1 but little P-gp, suggesting that intrinsic drug resistance 
may be caused by MRP-1 and not P-gp. This observation has been further confirmed by 
studies on PDA cell lines that shows 97% of the PDA cell lines express MRP1 [100].  
PI3K and Chemoresistance: 
Another common mechanism by which cancer cells acquire drug resistance is 
through enhanced activation of the pro-survival pathways PI3K/Akt and Erk1/2 , which 
interferes with apoptosis of cancer cells. PI3K constitute a family of lipid kinases that has 
the catalyzes the phosphorylation of hydroxyl group of phosphatidylinositols (PIs) at 
their 3-position to form PI(4,5)P2 to PI(3,4,5)P3. The eff ct of PIP3 is mediated through 
its specific interaction with PDK1 and Akt/PKB, which are criti al mediators of PI3K 
signaling cascade (Figure 2.4) [101]. 
PI3K are heterodimers, consisting of the regulatory subunit p85 and the catalytic 
subunit p110. Binding of the p85 subunit to the phosphotyrosine co sensus motif on 
receptor tyrosine kinases (RTK) or G-protein coupled receptors, leads to allosteric 
activation of the catalytic subunit. Studies have shown that p85 binds to the consensus 
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sequence of MUC1 CT (phosphor tyrosine at YHPM motif of MUC1 CT) via its SH2 
domain. Upon binding to the consensus sequence motif, p85 is activated, which in turn 
activates the catalytic subunit p110 [59], [68]. Hence PI3K pathway is often observed in 
MUC1 high cancer cells. Studies have shown that MUC1 overexpression in breast, colon 
and thyroid cancer cells exhibit overactivated Erk1/2 and PI3K pathways, which is linked 
to their unresponsiveness to chemotoxic agents [68], [102]. Recently a link has been 
shown between activation of activation of PI3K/Akt pathway and  upregulation of 
ABCC1 gene expression in prostate cancer cells [103].  
Pancreatic cancer is one of the most difficult malignancies to treat because of its 
aggressive and drug resistant nature. An understanding of the mechanism of drug 
resistance in PC is needed for developing strategies that would improve the outcome of 
chemotherapy.  Thus, the goal of the present study was to firs  determine if MUC1-
overexpression in PDA cells makes them resistant to chemotherapeutic drugs and second 
to delineate the mechanism by which MUC1-associated resistance occurs. We report that 
MUC1 regulates the mdr gene expression via both Akt dependent and independent 
pathways, which confers the MDR phenotype to PDA cells. This is the first report that 
demonstrates a direct relationship between expression of MUC1 and mdr genes, in 
particular ABCC1 in pancreatic cancer. 
2.2. Materials and Methods  
Cell culture and Establishment of Stable Cell Lines Expressing MUC1: 
BxPC3 (American Type Culture Collection, Manassas, VA, USA) is a human 
PDA cell line that express very little endogenous MUC1. For retroviral infection, GP2-
293 packaging cells (stably expressing the gag and pol proteins) were co-transfected with 
the full length MUC1 construct or an empty vector expressing the VSV-G envelope 
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protein as previously described [62], [63]. Cells were treated with 0.5 mg/ml of G418, 
beginning 48 h post infection. Three independent infections of the constructs were carried 
out with similar results. Expression of the constructs was stable throughout the span of 
experiments. Cells infected with vector alone were used a control and designated Neo. 
For MUC1-infected cells, MUC1-positive cells were sorted using the FACS Aria (BD 
Biosciences, San Jose, CA, USA). For Neo-infected cells, MUC1-negative cells were 
sorted. Capan-1 is a human PDA cell line that expresses high levels of endogenous 
MUC1. 
Mouse model and Mouse Cell Lines: 
In our laboratory, mice that develop spontaneous pancreatic du tal 
adenocarcinoma (PDA) were generated by mating the P48-Cre with the LSL-KRASG12D 
mice [104]. PDA mice were further mated to the MUC1.Tg mice (that express human 
MUC1) to generate PDA.MUC1 mice or to the Muc1 knockout mice to generate 
PDA.MUC1KO mice [58], [105]. All these mice were on the C57/B6 background. Cell 
lines were generated from the primary tumors of PDA.MUC1 and PDA.Muc1 KO mice 
and were designated as KCM and KCKO respectively.  
MTT assay and H3-Thymidine Incorporation Assays:  
10 X 103 cells were plated in quadruplicate in normal growth medium in 96-well 
plates and were permitted to grow for 18 hours. Cells were left untreated or treated with 
etoposide (Sigma-Aldrich) and gemcitabine (Sigma –Aldrich) for 24 hours. Next, MTT 
(Biotium) solution was added (10 ul/well) to cells, incubated for additional 3-4 hours. In 
the final step, media was removed, formazan was dissolved in DMSO (200ul/well) and 
the absorbance was read on an ELISA plate reader. 
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For H3-thymidine assay, 5 X 103 cells were plated and treated as described above. 
24 hours post drug treatment, H3-thymidine (Perkin Elmer, USA) was added in fresh 
medium (1 μCi/well) and cells were permitted to grow for another β4 hours. At this time, 
cells were washed to remove excess radioactivity, trypsinized, and harvested onto a filter 
plate, which was then read on a TopCount plate reader. The data has been represented as 
% difference in H3 – thymidine uptake, which represents the % decrease in proliferation 
or % in growth arrest. The following formula was used for calculations: 
 % difference in H3 thymidine uptake = ((cpm untreated – cpm treated)/ cpm 
untreated*100) 
Transient Knockdown Using siRNA: 
The method is previously described in [63]. In brief, cells were seeded in a 6 well 
plate and were allowed to reach 40% confluency. The cells were th n transfected with 
100nm of MUC1 siRNA (Smart genome pool) or 100 nm of Akt siRNA (Santa Cruz and 
Cell Signaling). Cells of the control group were treated with 100nm of scrambled siRNA 
(Dharmacon, Thermo Fischer Scientific, CO, USA, Santa Cruz and Cell Signaling). 
Lipofectamine (Invitrogen, San Diego, CA, USA) was used for the delivery of siRNA 
into the cells over a period of 5-6 hours in serum free Opti-MEM. 48 hours post 
transfection, MUC1 and Akt expression were evaluated by western blot. For MTT assay, 
36hours post siRNA treatment; cells were trypsinized, re-plated in a 96 well plate and 
treated with or without the drugs. MTT assay was performed 24 hours post drug 
treatment. The viability of each treatment group without drg t eatment (i.e. WT alone, 
control siRNA alone and Akt siRNA alone) was considere  as 100%. The viability 
following drug treatment on each of these treatment groups was calculated as follows: 
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% viability of drug treated WT cells = (O.D. of drug treated WT cells/O.D. of WT 
cells)*100  
% viability of drug + control (or Akt) siRNA treated cells = (O.D. of drug + control (or 
Akt) siRNA treated cells/O.D. of control (or Akt) siRNA treated cells)*100 
Preparation of Nuclear Extract:  
Cells were grown in 10cm plate. When the cells reached around 80% confluency, 
they were scraped off the plate and nuclear extraction kit (EMD Millipore)  was used to 
isolate the nuclear and cytosolic fractions.  
Western Blots:  
Equal quantities of cell lysates were loaded on SDS–PAGE gels. MUC1 
antibodies were a gift from Dr. Sandra Gendler. pAkt and Akt antibodies were purchased 
from Cell Signaling Technology (Danvers, MA, USA), MRP-1, Lamin A/C and β-actin 
were purchased from Santa Cruz (CA, USA) and MEK1 was purchased from Abcam 
(Boston, USA). The antibodies were used according to manufacturer‟s recommendations.  
Semi-Quantitative RT-PCR:  
 Total RNA was extracted from cells by TRIzol (Invitrogen) according to the 
manufacturer‟s protocol. 1–β μg of the extracted RNA was used as template for RT-PCR 
reaction (Access quick RT-PCR kit, Promega, Madison, WI, USA). Sequence of the 
primers is available upon request. 
Immunohistochemistry: 
Cells (1X106 cells per mouse) were implanted subcutaneously in nude mice and 
30 days later, tumors were collected for IHC and protein lysate [62]. In brief, paraffin 
embedded blocks of formalin fixed tumor sections were made by the Histology Core at 
Mayo Clinic. 4 micron thick sections were prepared for immunohistochemical staining. 
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MRP1 expression in the tumor was determined using anti-MRP1 antibody (1:50 dilution, 
Santa Cruz) followed by appropriate secondary antibody (1:100 dilution, Dako). Slides 
were examined under light microscope and pictures were taken at 20X.  
Chromatin Immunoprecipitation (ChIP):  
Cells grown to near 80% confluence, were cross-linked with formaldehyde 
(Sigma) at room temperature for 10 min. Cross-linked chromatin prepared with a 
commercial ChIP assay kit (EZ-Magna ChIP; Millipore) was immunoprecipitated with 20 
μg of normal Armenian hamster IgG (Santa Cruz Biotechnology, CA, USA) and  β0 μg 
of anti-MUC1 CT antibody (CT2). MUC1 CT binding site on ABCC/Abcc1 promoter was 
amplified by PCR using the input DNA (1%) or DNA isolated from precipitated 
chromatin as templates and using primers flanking the promoter region 1000 bp upstream 
(ChIP region I) and 2000bp upstream (ChIP region II) of ABCC1/Abcc1 gene (Fig. 6B). 
ChIP region II was used as a negative control for binding of MUC1 CT to the promoter 
region. Sequence of the primers is available upon request. 
Statistical Analysis: 
Statistical analysis was performed with GraphPad software.  
2.3. Results  
To determine the relative expression of endogenous MUC1 in BxPC3 and Capan-
1 cell lines, immunohistochemical analysis of cells grown in chamber slides was 
performed using an antibody against the tandem repeat of MUC1 (HMFG2). 
Immunohistochemical staining showed that Capan-1 cells have higher endogenous 
MUC1 expression as compared with BxPC3 cells (Figure 2.6a). This was confirmed 
using western blotting assay using antibodies against the tandem repeat (HMFG2) and 
CT of MUC1 (CT2). Both antibodies showed that Capan-1 cellshave higher endogenous 
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MUC1 compared with BxPC3 cells (Figure 2.6b). Next, we show MUC1 expression in 
Capan-1 cells following treatment with control and MUC1-specific siRNA (small 
interfering RNA) by western blot. Complete knockdown of MUC1 is observed in Capan-
1 cells post 48-h treatment with MUC1-specific siRNA (Figure 2.6c and supplementary 
table 2.1). To determine the effect of MUC1 in drug resistance, BxPC3 and Capan-1 cells 
were treated with etoposide and gemcitabine, and proliferation post treatment was 
determined using H3-thymidine incorporation assay. Etoposide is a toposiomerase II 
inhibitor, whereas gemcitabine is a nucleoside analog. Low MUC1-expressing BxPC3 
cells showed greater sensitivity to etoposide and gemcitabine compared with high 
MUC1-expressing Capan-1 cells. At 25 μM dose of etoposide, we observed a 6β.8% 
growth arrest in BxPC3 cells. In contrast, at the same dose, only 12.14% growth arrest 
was observed in Capan-1 cells (Figure 2.6d) Similarly, at 500 nM dose of gemcitabine, 
~100% growth arrest was observed in BxPC3 cells, compared with only 50% growth 
arrest in Capan-1 cells (Figure 2.6e). Further, when Capan-1 cells treated with MUC1 
siRNA were exposed to 500 nM of gemcitabine, a 31% increase in growth arrest was 
observed compared with untreated cells or cells transfected with control scrambled 
siRNA (Figure 2.6f).   
For further investigations, mouse PDA primary cells genetically lacking Muc1 
(KCKO) and ones expressing human MUC1 (KCM) were included in this study. Upon 
using the CT2 antibody that recognizes the CT of both mouse and human MUC1, KCM 
cells showed high expression of MUC1 while KCKO cells showed no etectable levels 
(Figure 2.7a and supplementary table 2.2). To further validate the ffect of MUC1 in drug 
resistance, KCKO and KCM cells were treated with etoposide and gemcitabine. We 
found 76% and 88% of growth arrest upon treatment of KCKO cells with 1.25 μM and 
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2.5 μM of etoposide, respectively. In contrast, only 5β% and 57% of growth arrest was 
observed in KCM cells at 1.25 and 2.5 μM of etoposide, respectively, indicating that 
KCM cells were more resistant to etoposide (Figure 2.7b left panel). At 5 μM of 
etoposide, both cell lines irrespective of their MUC1 status were sensitive. Similar 
resistance of KCM cells to gemcitabine was observed. At 3 nM of gemcitabine, 60% of 
growth arrest was observed in KCKO cells compared with only 34% of growth arrest in 
KCM cells. At higher doses, there was no difference in growth arrest between KCKO and 
KCM cells (Figure 2.7b, right panel). MTT assay was also performed to validate the 
cytotoxic effects of these drugs on the same cell lines. At 50 μM of etoposide, 48% of 
cell death was observed in KCKO cells compared with only 27% cell death in KCM cells 
(Figure 2.7c, left panel). Similarly, at 150 nM of gemcitabine, 53.3% of cell death was 
observed in KCKO cells compared with only 40% cell death in KCM cells (Figure 2.7c, 
right panel). 
To further confirm that the effect was due to MUC1 expression, we stably 
expressed full-length MUC1 in BxPC3 cells that have low levels of endogenous MUC1 
(BxPC3.MUC1), and as control we transfected BxPC3 cells with empty vector that 
contains the neomycin resistance gene (BxPC3.Neo). First we show the relative 
expression of MUC1 in these cells (Figure 2.8a and supplementary table 3).  BxPC3 
MUC1 cells express high levels of MUC1 while BxPC3 Neo cells have negligible levels. 
BxPC3 MUC1 cells were significantly resistant to both the genotoxic drugs as compared 
with the BxPC3 Neo cells. At 25, 50 and 75 μM of etoposide, cells with low MUC1 
showed significantly higher growth arrest compared with cells expressing high levels of 
MUC1 (Figure 2.8b, left panel). Similar results were observed with 6.25–25 nM of 
gemcitabine (Figure 2.8b, right panel). MTT assay was performed to validate the 
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cytotoxic effects of etoposide and gemcitabine on both cell lin s. At 75 μM of etoposide, 
64% of cell death was observed in BxPC3 Neo cells compared with only 39.6% cell 
death in BxPC3 MUC1 cells (Figure 2.8c, left panel). Similarly, at 50 nM of gemcitabine, 
42.7% of cell death was observed in BxPC3 Neo cells compared with only 15.5% cell 
death in BxPC3 MUC1 cells (Figure 2.8c, right panel). These reults suggested that 
MUC1 confers resistance to gemcitabine and etoposide in PDA cells. 
Previously we have published that KCM cells express 8-fold higher P-
glycoprotein, 4-fold higher MRP-1, and 2-fold higher MRP-5 protein compared to 
KCKO cells [58]. Therefore, we first determined the mRNA level of some of these MDR 
genes. Consistent with those results, we observed significantly high m-RNA levels of the 
Abcc1, Abcc3, Abcc5, Abcb1a and Abcb1b genes in KCM versus KCKO cells (Figure 
2.9a, left panel). Similarly, in BxPC3 MUC1, the m-RNA levels of ABCC1, ABCC3, 
ABCC5, and ABCB1 gene was significantly higher compared to BxPC3 Neo cells (Figure 
2.9a, right panel). To validate this finding, we determined the protein expression of MRP-
1 by western blotting and as expected we observed significantly higher expression of 
MRP-1 in KCM cells compared to KCKO cells and in BxPC3 MUC1 compared to 
BxPC3 Neo cells (Figure 2.9b).  
All of the data so far has been shown in cells grown in vitro. To answer if this is 
true in vivo, we determined the MRP-1 protein expression in spontaneously occurring 
PDA.MUC1 (KCM) and PDA.Muc1KO (KCKO) tumors as well as in BxPC3 Neo and 
MUC1 tumors grown in nude mice. IHC was performed on tumor sections from ~16-
week old KCM and ~24-week KCKO mice and a representative section from each tumor 
type is shown in Figure 2.9 c. Significantly higher expression of MRP-1 protein was 
observed in KCM as compared to KCKO tumor sections (Figure 2.9 c). MRP1 levels in 
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the tumor lysates isolated from BxPC3 Neo and BxPC3 MUC1 xenografted tumors were 
determined by western blotting. BxPC3 MUC1 tumors showed higher MRP-1 expression 
compared to BxPC3 Neo tumors (Figure 2.9 d). Interestingly, the tumor sample (sample # 
3) that had higher MUC1 expression compared to the other MUC1 positive tumor sample 
(sample #4) also showed higher MRP-1 expression (Supplemental table 5). The data 
suggests that a positive correlation exits between MUC1 overexpression and upregulation 
of mdr genes in PDA cells. 
Often in tumor cells, reduced sensitivity to chemotherapeutic drugs is due to 
enhanced activation of the anti-apoptotic or prosurvival pathways, which includes the 
PI3K/Akt pathway. We first determined the activation status of PI3K/Akt pathway in 
KCKO, KCM, and BxPC3.Neo and BxPC3.MUC1 cells. Protein lysate  from these cell 
lines were subjected to immunoblotting using anti-phospho-Akt (p-Akt) and Akt 
antibodies. Significantly higher levels of pAkt was found in MUC1 positive PDA cells 
(KCM and BxPC3 MUC1) compared to MUC1 low or null PDA cells (KCKO and 
BxPC3 Neo) (Figure 2.10 a). The levels of total Akt remained same in all cell lines 
indicating enhanced activation of the PI3K/Akt pathway in KCM and BxPC3 
MUC1cells. This finding positively correlates with the results presented previously in 
MUC1 overexpressing fibroblasts[68].   
To test the contribution of Akt on MRP1 expression and drug resistance, we 
transiently knocked down Akt and evaluated the levels of MRP1 expression by western 
blot and drug sensitivity by MTT assay. The levels of Akt, MRP1 and MUC1 are shown 
in Figure 2.10 b - d. Upon Akt knockdown, we observed a 5.4 fold decrease in MRP1 
expression in Capan-1 cells and 4.6 fold decrease in MRP1 expression in BxPC3 MUC1 
cells (Figure 2.10b, 2.10c, Supplemental table 7 & 8). Furthermore, roughly 40% and 
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25% increase in cytotoxicity was observed in Akt siRNA treated BxPC3 MUC1 cells 
upon treatment with 50µM of etoposide and 25nM of gemcitabine respectively (Fig.  
2.10E).This data indicated that Akt pathway played an important ole in MUC1 induced 
MRP1 expression and drug resistance in Capan1 and BxPC3 cells.  
Interestingly, we also observed a subsequent decrease in MUC1 expression upon 
downregulation of Akt in Capan-1 and BxPC3 MUC1 cells (Fig 2.10b, 2.10c). When Akt 
was transiently knocked down in Capan-1 and BxPC3 MUC1 cells, a respective 3.2 fold 
and 2.5 fold decrease in MUC1 expression was observed (Supplemental table 7 & 8). 
This data indicates that MUC1 gene is also under regulation of PI3K/Akt pathway. 
Hence, abrogation of the Akt pathway causes a significant decrease in MUC1 expression, 
which in turn negatively affects MRP1 expression.  
However, we did not see a significant decrease in MUC1 and MRP1 expression in 
KCM cells upon Akt knockdown (1.2 fold decrease) (Fig 2.10d) (Supplemental table 9). 
Consequently, we did not detect a significant increase in cytotoxicity in Akt siRNA 
treated KCM cells upon treatment with etoposide and gemcitabine (data not shown). This 
data indicates that in KCM cells, MUC1 gene is not strongly regulated by PI3K/Akt 
pathway. This observation further led to the possibility that in KCM cells, an Akt 
independent mechanism must be involved in MUC1 induced MRP1 expression and drug 
resistance. It is of interest that BxPC3 and Capan-1 are human cells while KCM is a 
mouse cell line.  
Several studies have shown that MUC1 CT associates with mediators of signal 
transduction and transcriptional regulation and thereby modifies the expression of 
specific target genes [63][64]. In this study, we wanted to investigate the occupancy of 
MUC1 CT in the promoter region of ABCC1/Abcc1 gene, which can be indicative of 
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MUC1‟s role as a modulator of ABCC1/Abcc1 gene expression. First, we demonstrate 
that MUC1 CT localizes to the nucleus of MUC1 positive PDA cells. Nuclear and 
cytosolic fractions were extracted from KCKO, KCM, BxPC3 Neo and BxPC3 MUC1 
cells and the lysates were immunoblotted to determine the cellular localization of MUC1 
CT in these PDA cells. As expected, we found MUC1 CT localizing to the nucleus of 
KCM cells (left top panel Figure 2.11a) and BxPC3 MUC1 cells (right top panel Figure 
2.11a). Lamin A/C and MEK1 served as controls for the extraction process. Lamin A/C is 
a nuclear protein and is hence is found only in the nuclear fractions (middle panels, 
Figure 2.11a). MEK1 is a cytosolic protein and is found only in the cytosolic fractions 
(bottom panels Figure 2.11a).  
Next, we evaluated the occupancy of MUC1 CT in the genomic regions of the 
ABCC1/Abcc1 gene upstream the transcription start site (Figure 2.11b). Sheared DNA 
was immunoprecipitated using MUC1 CT specific antibody CT2. IgG antibody was used 
as a control. The immunoprecipitated DNA was amplified by PCR using primers 
spanning around 1000 bp upstream (ChIP region I) and 2000bp upstream (ChIP region II) 
of the ABCC/Abcc1 gene  transcription start site (Figure 2.11bB). In Capan-1 cells, we 
observed a strong interaction between MUC1 CT and ChIP region I of ABCC1 gene (6.5 
fold enrichment with CT2 antibody relative to IgG) (Figure 2.11c, Supplemental table 
10). Similarly, in KCM cells, a strong interaction was observed between MUC1 CT and 
ChIP region I of Abcc1 gene (3.2 fold enrichment with CT2 antibody relative to IgG) 
(Figure 2.11c, Supplemental table 11). However, no interaction was observed between 
MUC1 CT and ChIP region II in Capan-1 and KCM cells (Figure 2.11c). KCKO cells, 
which are null for MUC1 did not show any interaction between MUC1 CT and ChIP 
region I and II of  Abcc1 gene (Figure 2.11c). This data indicated that the interaction of 
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MUC1 CT with the promoter region of ABCC1/Abcc1 gene around ChIP region I is 
specific. However, in BxPC3 MUC1 cells, a very weak interaction between MUC1 CT 
and ChIP region I of ABCC1 gene was observed (1.1 fold enrichment compared to IgG, 
Supplemental table 12) (Figure 2.11c). BxPC3 Neo cell also showed weak binding of 
MUC1 CT around the same gene locus. This is most likely becaus BxPC3 cells express 
low levels of endogenous MUC1 and are not null for the same (Figure 2.11c). The 
interaction between MUC1 CT and ChIP region II was not observed in BxPC3 cells 
(Figure 2.11b). 
2.4. Discussion  
The ability of tumor cells to escape the cytotoxic effect of chemotherapeutic 
agents may result from genetic alterations that affect cell ycle, apoptosis or 
accumulation of drugs inside the cell. Several studies in breast, colon and thyroid cancers 
have shown that MUC1 attenuates stress induced or chemotoxic agents induced apoptosis 
by blocking the release of cytochrome c from mitochondria [68], [102], [106]. In this 
study, we demonstrate additional mechanisms by which MUC1 enables PDA cells to 
escape chemotherapeutic drug mediated cell death.   
We found that cells expressing full length MUC1 are less sensitive to genotoxic 
drugs than cells lacking or expressing low levels of MUC1, indicating a direct correlation 
between MUC1 expression and chemoresistance in PC (Figure 2.6, 2.7 and 2.8). Here, 
for the first time, we provide evidence that in PDA cells, mdr gene expression is directly 
correlated with MUC1 expression (Figure 2.9). Previous work has shown that 
hyperactivation of PI3K/Akt pathway is able to regulate expression of mdr genes, 
including ABCC1, ABCC3, ABCC5, and ABCB1 genes [103]. Studies have demonstrated 
that MUC1 oncoprotein induces transformation in rat fibroblasts or desensitizes thyroid 
54 
 
cancer cells to chemotherapy induced apoptosis through activation of Jak/Stat and 
PI3K/Akt pathways [68][102]. So, we evaluated if MUC1 induced expression of the mdr 
gene ABCC1/Abcc1 via activating the PI3K/Akt pathway. We found that in a subset of 
human PDA cells (BxPC3 MUC1 and Capan-1), MUC1 induced MRP1 expression was 
via Akt pathway with a pattern that suggests increased refractoriness of these cells to 
genotoxic drugs. Accordingly, abrogation of the PI3K/Akt pathway resulted in increased 
responsiveness of these cells to etoposide and gemcitabine (Figure 2.10).  We also found 
the evidence for existence of a positive feedback loop between MUC1 expression and 
PI3K/Akt signaling cascade. PDA cells with high MUC1 expression exhibited hyper 
activation of the PI3K/Akt pathway which in turn upregulated MUC1 expression in those 
PDA cells. However, it is beyond the scope of the current study to determine how Akt 
pathway regulates MUC1 expression. In the future, we would like to investigate the 
mechanism in further detail. Interestingly, in the mouse PDA cells, KCM, MUC1 induced 
MRP1 expression was independent of PI3K/Akt pathway even though the pAkt was 
significantly higher in the KCM versus KCKO cells. This data underscored the 
possibility of involvement of an alternative mechanism involved in MUC1-induced 
MRP1 expression (Figure 2.11). Thus, we report for the first time that two alternate 
mechanisms may be involved in MUC1-induced MRP1 expression in PDA cells (Figure 
2.12).  
Interestingly, we found a strong association between MUC1 CT and the promoter 
region of the ABCC1/Abcc1 gene (Figure 2.11). This preliminary data raises a possibility 
that MUC1 might be part of the transcriptional complex that regulates expression of the 
ABCC1/Abcc1 gene. The 5‟ untranslated promoter region of the human ABCC1 gene 
contain several putative binding sites such as, GC elements (-91 to +103) which binds 
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Sp1; AP1 sites (-511 to -492) which binds a complex of cJun/cFos and E box elements (-
1020 to -2008) which binds N-myc [106], [107], [108]. We found MUC1 CT associating 
with the promoter region of the ABCC1/Abcc1 gene within ChIP region I. Both mouse 
and human ChIP region I contain putative AP1, CREB1, GATA1, c-Ets1 and MZF1 
binding motifs, as predicted by the transcription factor binding site prediction tools that 
uses TRANSFAC and JASPAR core databases (data not shown).  MUC1 does not have a
DNA - responsive domain and studies have shown that it binds to DNA via transcription 
factors such as NF-kB, cJun, β-catenin and HIF-1α [60], [63], [64]. Thus, in future we 
intend to investigate in detail what MUC1 CT is doing at thepromoter region of 
ABCC1/Abcc1 gene and also the transcription factor that is involved in MUC1 mediated 
MRP1 gene expression.  
Taken together, our study shows that, in PC cells, MUC1 overexpression leads to 
chemoresistance, and that MUC1 CT associates directly with the promoter region of 
the ABCC1/Abcc1 gene. Thus, the data provide new insights into the mechanisms by 
which MUC1 can interfere with the effectiveness of chemotherapy in PC. As MUC1 acts 
as a vital component that minimizes the efficacy of chemotherapy, it could be considered 
as a key molecular target for sensitizing cancer cells to conventional or novel treatments. 
The CT of MUC1 can be targeted to inhibit its ability to initiate signaling cascades, and 
also to block its nuclear translocation and subsequent binding to the promoter regions of 
its target genes. MDR modulators did not gain much popularity in the clinic owing to 
their ability to regulate more than one transporter and subsequently causing severe side 
effects in patients. [89]. As an alternative strategy, MUC1 CT can be targeted to 
downregulate the expression of mdr genes or the activity of these efflux pumps.   
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2.5. Figures  
 
Figure 2.1: Classification of the cancer resistance intotw  broad types: de-novo or 
acquired resistance. A. De-novo resistance consists of presence of multiple drug resistant 
sub population of cancer cells, which emerge as the dominant clone following 
chemotherapy treatment. These subpopulations of cells pos ess stem cell like properties 
and are believed in dormancy, thus escaping the insults of chemotherapy. B. Acquired 
drug resistance results from alterations in the cancer cell following exposure to 
chemotherapy. In both cases the surviving cell population are likely not to respond to 
chemotherapy and will be responsible for the relapse of the disease  [109]. 
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Figure 2.2: Chemoresistance caused by efflux of drugs by ABC transporters: ABC 
transporters effelux drugs and prevent accumulation of drugs inside the drug resistant 
cancer cells. The drug sensitive cells are eradicated by the chemotherapeutic drugs.  
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Table 2.1: The different members of ABC pumps and their substrate  [89]. 
 
 
 
 
 
 
 
 
 
59 
 
 
 
Figure 2.3: Basic structure of ABC transporters: ABC transporters consist of an aqueous 
pore with a large opening towards the extracellular region. The aqueous pore is made up 
of transmembrane domains (TMD), which spans the lipid bilayer of cell membrane. The 
nucleotide binding domain (NBD) which is partly embedded into the lipid bilayer faces 
the cytosolic part [95]. 
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Figure 2.4: Schematic representation of the topological features of the ABC transporters:  
ABCB1 contains two transmembrane domain (TMD) and two nucleotide binding domain 
(NBD). In contrast ABCC1 contains three TMD and 2 NBD [96].  
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Figure 2.5: Activation of PI3K pathway. [101] 
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Figure 2.6: MUC1 expression and drug sensitivity of a panel of cancer cells: (a) Staining 
of endogenous MUC1 expression in BxPC3 and Capan-1 cells using HMFG2 antibody, 
Capan-1 expresses high levels as depicted by the brown staining whereas BxPC3 cells 
have negligible levels of MUC1 staining. (b) Western blot analysis of MUC1 expression 
in BxPC3 and Capan-1 cells by western blot using HMFG2 and CT2 antibody. (c) 
Western blot analysis of MUC1 expression in Capan-1 cells following treatment with 
MUC-1 specific siRNA (48 h). (d, e) H3-thymidine incorporation to measure proliferation 
in PDA cells following 24 h treatment with etoposide and gemcitabine (n=4). 
Significantly higher proliferation was observed in Capan-1 cells, which express high 
levels of MUC1 (***P<0.001). (f) Percent difference in H3-thymidine uptake in control 
siRNA and MUC1 siRNA treated cells as a function of Capan-1 WT cells. Cells were 
treated for 24 h with 500 nM of gemcitabine (n=4). Cells treated with MUC1 siRNA 
showed significantly reduced proliferation in response to gemcitabine as compared with 
untreated or control siRNA treated cells (**P<0.05). 
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Figure 2.7: Endogenous expression of MUC1 in PDA cells confers resi tance to cytotoxic 
drugs: (a) Western blot analysis of endogenous Muc1/MUC1 expression in mouse cells 
lines KCKO and KCM using CT2 antibody. Note: CT2 is the only antibody that 
recognizes both mouse and human Muc1/MUC1. (b) Percent difference in H3 thymidine 
uptake in KCKO and KCM cells following 24 hours treatment with etoposide, and 
gemcitabine. Significant differences between KCKO and KCM cells at varying 
concentrations of the drugs is shown as p-values (n=4) (**p<0.01, *** p<0.001). (c) Cell 
viability in KCKO and KCM cells following 24 hours treatment with etoposide, and 
gemcitabine. Significant differences between KCKO and KCM cells at varying 
concentrations of the drugs is shown as p-values (n=6) (*p<0.1, **p<0.01, *** p<0.001). 
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Figure 2.8: Exogenous expression of MUC1 in BxPC3 cells confers resi tance to 
cytotoxic drugs. (a) Western blotting analysis of MUC1 expression in BxPC3 cells using 
CT2. (b) Percent difference in H3 thymidine uptake of BxPC3 Neo and MUC1 cells 
following 24 hours treatment with etoposide and gemcitabine ( =4). Significant 
differences between BxPC3.Neo and MUC1 are shown (**p<0.01). (c). Cell viability in 
BxPC3 Neo and BxPC3 MUC1 cells following 24 hours treatment with etoposide, and 
gemcitabine. Significant differences between BxPC3 Neo and BxPC3 MUC1 cells at 
varying concentrations of the drugs is shown as p-values (n=6) (p<0.1, **p<0.01, *** 
p<0.001). 
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Figure 2.9: MUC1-positive PDA cells express elevated levels of MDR genes in vitro and 
invivo. (a) RT-PCR data showing fold changes in the m-RNA level of MDR genes that 
are associated with multidrug resistance. (b) Levels of MRP1 protein in BxPC3 Neo, 
MUC1, KCKO and KCM cell lysates analyzed by western blot. (c) IHC of MRP1 
expression in the tumor sections from KCKO (24 weeks old) an KCM (16 weeks old) 
mice. Note: Two different time points were deliberately selected since the tumor burden 
in the KCKO mice at 24 weeks is equivalent to the tumor burden in 16-week old KCM 
mice. (d) Levels of MRP1 protein in BxPC3 Neo and MUC1 tumor lysates were 
determined by western blot. 
 
 
66 
 
 
 
Figure 2.10: MUC1 induces MRP1 expression via Akt- dependent and -indepe dent 
pathways. (a) BxPC3 Neo, MUC1, KCKO and KCM cell lysates were subjected to 
western blot analysis to determine phosphorylation of Akt. Level of unphosphorylated 
Akt served as control for phosphorylation. β-actin served as loading control. (b–d) Cells 
were treated with with 100 nM of Akt siRNA for 48 h, and the lysates were 
immunoblotted to evaluate the lvels of Akt, MRP1 and MUC1. β-actin served as a 
loading control. (e) Cells growing in a 6-well plate were left untreated (WT) or treated 
with either control siRNA or Akt siRNA (100 nM). Thirty-six hours post treatment, cells 
were trypsinized, and equal number of cells was re-plated in a 96-well plate. The cells 
were allowed to adhere and, at 48 h, were left untreated or treated with 50 μM of 
etoposide and 25 nM of gemcitabine. MTT assay was performed to measure cytotoxicity 
24 h post drug treatment. 
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Figure 2.11: ChIP–PCR assay reveals an interaction between the MUC1 CT and the 
ABCC1 promoter region. (a) Nuclear lysates of KCKO, KCM, BxPC3 Neo and BxPC3 
MUC1 cells were subjected to immunoblotting to determine the nuclear localization of 
MUC1 CT. Lamin and MEK1 were used as controls for nuclear and cytosolic fractions, 
respectively. (b) Schematic representation of the primers that were designed to PCR 
amplify the promoter region of human ABCC1 gene (top panel) and mouse Abcc1 gene 
(bottom panel) in ChIP assay. (c) ChIP–PCR; lanes include: Input DNA, DNA 
precipitated using control IgG and CT2, and amplified by PCR using Taq polymerase and 
separated by 2% agarose gel. 
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Figure 2.12: Schematic illustration of the two possible pathways by which MUC1 
regulates MRP1 gene expression in PDA cells.  In human PDA cell lines, Capan-1 and 
BxPC3 MUC1, MUC1-induced ABCC1 gene expression is dependent on PI3K/Akt 
pathway. The CT of MUC1 stimulates the PI3K/Akt pathway, which in turn increases 
MUC1 expression (left panel). In murine PDA cell line, KCM, UC1-induced MRP1 
expression is independent of the PI3K/Akt pathway (right panel). The CT of MUC1 
translocates to the nucleus and binds to the promoter of ABCC1/Abcc1 gene, possibly 
acting as a part of the transcriptional complex that drives the expression of this gene (left 
and right panels). 
 
 
 
 
 
 
 
 
 
    
                      
 
CHAPTER 3: MUC1 POSITIVE PANCREATIC CANCER CELLS ACQUIRE GROWTH 
AND METASTATIC ADVANGTAGE THROUGH UPREGULATION OF COX-2 GENE. 
 
 
3.1 Introduction 
Cyclooxygenase (Cox) and prostaglandins (PGH): 
Cyclooxygenase (Cox), also known as prostaglandin H2 synthase are a class of 
membrane bound bi-functional enzymes that calatyzes the rate limiting step in the 
conversion of arachidonic acid to prostaglandins (PGH). Prostaglandins include a large 
class of regulatory molecules, which mediate a wide array of crucial biological functions, 
such as regulation of immune function, inflammation, maintenance of gastrointestinal 
integrity, kidney development and reproductive biology [113].  Arachidonic acid (AA), 
an ω-6 polyunsaturated fatty acid (PUFA), abundantly distributed throughout the lipid 
bilayer is first oxidized to PGG2 by the oxygenase activity of C x enzyme, which is 
further reduced to PGH2 by the endoperoxidase activity of Cox (Figure 3.1) [110]. Less 
commonly, Cox enzymes also catalyze conversion of Di-homo-け-linolenic acid (DHLA) 
to PGH1 and eicosapentaenoic acid (EPA), a ω-3 fatty acid to PGH3. PGH2 is further 
converted into different isoforms by tissue specific isomerases (Figure 3.2). Prostaglandin 
E (PGE) isomerase is found in most cell types and PGE2 is the most abundant isoform.  
Cox isoforms and their tissue expression profile:  
Initially COX was thought to be a single enzyme that catalyzes the rate limiting 
step in the conversion of arachidonic acid to PGH. However, it soon became apparent 
that there are different isoforms of Cox, which have different expression profile and 
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physiological functions. Cox-1 is expressed constitutively in tissues such as kidney, lung, 
stomach, duodenum, jejunum, ileum, colon, and cecum. In contrast, Cox-2 is an inducible 
enzyme or early response gene. The basal level expression of Cox-2 is absent in most 
tissues, with the exception of CNS and kidney, which constitutively expresses Cox-2 
[111]. LPS, tumor necrosis factor (TNF), interleukin (IL), interferon – γ,  serum,  
epidermal growth factor (EGF), platelet activating factor (PAF), tumor growth factor -α 
(TGF-α), endothelin and arachidonic acid are some of the factors that induces Cox-2 gene 
and increases its expression in tissues [112]. Within a few hours of stimulation, the gene 
is induced, causing a spike in the levels of Cox-2 mRNA and protein, which returns to 
basal level within 24 hours of stimulation [111].  
Cox genes, transcripts and proteins: 
Cox isoforms are encoded by two different genes (PTGS1/Ptgs1 and 
PTGS2/Ptgs2), which are located on different chromosomes.  Cox-1 is transcribed by 
Ptgs1 gene, located on human chromosome 11, whereas Cox-2 is transcribed by Ptgs2 
gene, located on human chromosome 1. Ptgs1 gene consisting of 11 exons transcribes a 
2.8kb long transcript. In contrast, Ptgs2 gene, consisting of 10 exons transcribes a 4 kb 
long transcript. The Cox-2 mRNA is relatively short lived due to the presence of „Shaw 
Kamen instability‟ elements in the γ‟UTR that affects its stability [111]. Inspite of 
substantial difference in the length and sequence of the transcripts, Cox-1 and Cox-2 
proteins are very similar in length and molecular weight. Both Cox-1 and Cox-2 exits as 
homodimers in solution. Both Cox-1 and Cox-2 monomers are ~600 amino acids long 
and the molecular weight is ~71KD. Sequence homology study revealed 60%-65% 
sequence similarity between Cox isoforms from the same species and 85% - 90% 
sequence similarity between orthologs of different species[110]. 
71 
 
General structure of Cox and the isoform specific structual differences: 
The crystal structure shows significant three-dimensional structural homology 
between the different isoforms of Cox [113]. Broadly, the COX monomer consists of 
three domains: the N-terminal EGF like domain, a membrane binding domain (MBD) of 
about 48 amino acids, and a large C-terminal globular catalytic domain (Figure 3.4).  The 
exact function of the EGF domain is still not known. The MBD domain comprises of β
sheets which allows mototypic insertion of the enzyme into the lipid bilayer. The Cox 
catalytic domain constitutes bulk of the enzyme, which comprises of peroxidase (POX) 
catalytic site, cyclooxygenase (COX) active site and heme prosthetic group. POX active 
site lies in a large groove opposite to the MBD. The COX catalytic site is situated 
opposite to the POX site and heme prosthetic (Figure 3.4) group.  A 25A0 long 
hydrophobic L shaped Cox channel extends from the MBD to the active site of COX 
catalytic domain. The Cox channel contains several side pockets and water channels. The 
Cox channel tapers to form a narrow aperture which separates the channel from the Cox 
catalytic site (Gly 533). 24 non-polar amino acids and only 3 polar amino acids line the 
hydrophobic COX active site [114]. Arg120 binds the carboxylate group of arachidonic 
acid (AA) at the COX active site, whereas the ω-methyl group of AA lies at the narrow 
terminus of the channel. This places carbon-13 of AA in close proximity to Tyr-385, 
which is a critical amino acid required for the COX activity. The active site of Cox-2 is 
20% bigger and is of different shape in comparison to Cox-1. The cyclooxygenase active 
site in Cox-2 has 3 amino acids substitution. Ile 434, Ile 523 and His-513 in Cox-1 are 
substituted by Val-434, Val-523 and Arg-513 in Cox-2 [114]. This dramatically increases 
the substrate binding pocket of Cox-2 and consequently broadens its substrate specificity. 
Cox-1 and Cox-2 have same specificity for AA, but Cox-2 is more efficient at catalyzing 
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the conversion of bulkier fatty acids such as lenolenic ac d nd eicosapentanoic acid 
[111]. Another difference between Cox isoforms is that te length and sequence of amino 
acids vary considerably around the signal peptide in C-terminus. The signal peptide in 
Cox-2 consists of an 18 amino acids insert, 6 amino acids away from the end of the C-
terminal. However the insert does not disrupt the last 4 amino acids in the C-terminal, 
which contains the ER-targeting signal. It is believed that t e 18 amino acid insert in 
Cox-2 acts as a nuclear membrane targeting signal, which explains for the presence of 
Cox-2 in both ER and nuclear membrane [111].  
Both Cox-1 and Cox-2 are N-glycosylated at three sites (Asn68, Asn 144 and Asn 
410). Cox-2 is N-glycosylated at an additional site (Asn 588). Cox-1 is uniformly 
glycosylated, whereas, Cox-2 is heterogeneously glycosylated and hence the molecular 
weight of Cox-2 ranges from 65Kda to 80KDa [111]. Studies have shown that N-
glycosylation of Cox enzymes are required for the maturation of the protein but is not 
essential for their catalytic activity.  
Selective inhibitor of Cox-2 - Celecoxib: 
The classical non-steroidal anti-inflammatory drugs (NSAID), such as aspirin and 
ibuprofen are competitive cyclooxygenase inhibitors and theyinhibit enzyme activity of 
both Cox-1 and Cox-2. However, use of NSAID leads to serious side effects, such as 
gastric lesions and renal toxicity, as NSAID have higher specificity for Cox-1 enzyme 
and inhibition of Cox-1 activity leads to disruption of the cryoprotective function of Cox-
1 [113]. The 2nd generation Cox inhibitors, such NS398, Celecoxib, Refecoxib etc have 
reduced toxicity as they are specifically designed to inhibit the Cox-2 activity. Celecoxib 
has 100-1000 times more specificity for Cox-2 compared to Cox-1. Celecoxib, is 
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approved for clinical use by FDA and is routinely used for treating symptoms of 
osteoarthritis and rheumatoid arthritis [115].  
The Cox-1 and Cox-2 enzyme has minute structural differences around the 
opening of the Cox channel and catalytic site. These minute structural differences have 
been exploited for designing Cox-2 specific inhibitors. The last of the four helices in the 
MBD of Cox-2 is cantilevered upward, which creates a bigger opening of the Cox 
channel and allows bulkier celecoxib in accessing the catalytic site of Cox-2 (Figure 
3.5)[110]. Moreover, His-513 substitution to Arg-513 alters the chemical environment in 
the side pocket of the cyclooxygenase active site. Positively charged Arg-513 interacts 
with 4-methylsulfonyl of Celecoxib (Figure 3.6).  
Link between inflammation, cancer and Cox-2: 
Cox-1 is important for cryoprotection and for maintaining tissue homeostasis. In 
contrast, Cox-2 is expressed in response to growth factors and inflammation.  The link 
between cancer and inflammation has been long appreciated. Among a long list of 
proinflammatory molecules that has been closely linked to cancer, Cox-2 plays a critical 
role in the pathogenesis and progression of cancer. In a vast majority of malignancies, 
Cox-2 and its metabolite PGE2 is frequently overexpressed, an  its overexpression is 
associated with aggressive phenotype and poor prognosis of cancer. Cox-2 is important 
for both the initiation and progression of cancer. Cox-2 induces production of reactive 
oxygen species (ROS) and reactive nitrogen intermediates (RNI), which in excess can 
induce oxidative DNA damage leading to genetic mutations. Cox-2 allows cancer 
progression by promoting proliferation, invasion, metastasi, ngiogenesis, and resistance 
to apoptosis. Cox-2 is also known to attract and retain myeloid derived suppressor cells 
(MDSC), which suppress T cell activation and thereby causes profound immune 
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suppression around the tumor microenvironment [116], [117]..  The multifaceted role of 
Cox-2 in cancer underscores the importance of studying the regulation of Cox-2 gene 
expression in malignant cells.  
Previously, we reported that in PDA.MUC1 transgenic mouse, ovrexpression of 
MUC1 is detected at early stage PanIN lesions and its expression steadily increases as the 
cancer progresses. Similarly, a stage dependent increase in Cox-2 expression was 
observed in these mice (Figure 3.7) [118]. So, we asked ourselves the question, does 
MUC1 exert its tumorigenic effect in PDA via Cox-2/PGE2 signaling axis and if so does 
MUC1 directly regulates Cox-2 gene expression. In this paper, we eport for the first time 
that MUC1 directly regulates Cox-2 gene expression via NF-kB dependent pathway and 
that inhibition of Cox-2 leads to a reduction in the proliferation and invasive potential of 
the MUC1 high PDA cells.  
3.3 Materials and Methods 
Cell Lines and stable transfection:  
The human PDA cell lines Hs766T, Capan-2, HPAFII, HPAC and CFPAC, 
BxPC3, Capan-1 and Mia-Paca-2 were obtained from the ATCC (Manassas, Virginia, 
USA). Cells were cultured in DMEM, MEM and RPMI media supplemented with 10% 
fetal bovine serum (FBS), essential amino acids and antibiotic. The cells were maintained 
in 5% CO2, 95% air at 37°C. BXPC3 cells, expressing low levels of endogenous MUC1, 
were stably transfected with empty vector or full-length MUC1 construct expressing 
neomycin resistance gene as selection marker to generat  BxPC3 Neo and BxPC3 MUC1 
respectively [62]. Cells were selected with 0.5 mg/mL G418 for 48 hours post infection 
and were sorted using FACS Aria to isolate MUC1+ve cells.  Expression of the 
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constructs was stable throughout the span of experiments and the level of MUC1 
expression was validated using Western blot.  
Mouse model and mouse cell lines: 
In our laboratory, we generated mice that spontaneous develop pancreatic ductal 
adenocarcinoma (PDA) by mating the P48-Cre with the LSL-KRASG12D mice. PDA mice 
were further mated to the MUC1.Tg mice (that express human MUC1) to generate 
PDA.MUC1 mice or to the Muc1 knockout mice to generate PDA.MUC1KO mice. All 
these mice were on the C57/B6 background. Cell lines were generat d f om the primary 
tumors of PDA.MUC1 and PDA.Muc1 KO mice and were designated as KCM and 
KCKO respectively. Panc02 Neo and Panc02 MUC1 cell lines were generously donated 
by Dr. Michael Hollingsworth. 
Transient knockdown of target genes using siRNA:  
Cells plated in a 6well plate in antibiotic free complete media upon reaching 30% 
confluence were trasfected with 100-200nM of smart pool MUC1 siRNA 
(DHARMACON, Thermo Fisher Sc.) and 100-200nM of scramble control siRNA (Cell 
Signaling) using Lipofectamine 2000 (Invitrogen) for 5–6 hours in serum-free Opti-MEM 
(Invitrogen). Cells were washed with PBS and replenished with media supplemented with 
FBS. Whole cell lysates prepared 48, 72, and 96 hours post siRNA treatment were 
subjected to western blot to determine the efficiency of MUC1 knockdown. 
Western blots:  
Cell lysates were prepared using RIPA buffer and 30-60ug of protein w re 
subjected to denaturing SDS–PAGE and western blot. The PVDF membrane was probed 
with anti MUC1 antibody CT2, anti- NFkB (Cell Signaling Technology, Danvers, MA, 
USA), anti-Cox-2, anti- Lamin A/C and anti-β-actin (Santa Cruz, CA, USA) antibodies. 
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Appropriate secondary antibodies conjugated to HRP were sued and chemiluminescence 
kit was used for detection. All antibodies were used according to manufacturer‟s 
recommendations. 
Preparation of nuclear extract:  
Cells grown in 10cm plate upon reaching 85% confluence were lysed with 
appropriate buffers provided in the EMD Millipore nuclear extraction kit, to isolate the 
nuclear and the cytosolic fractions.  
Serum PGEM by ELISA: 
Serum PGE2 levels were determined using a specific ELISA kit (Cayman 
Pharmaceuticals, Ann Arbor, MI) that measures for the PGE2 metabolite (PGEM; 13,14-
dihydro 15-keto prostaglandin A2). The protocol was followed as recommended by the 
manufacturer. Results were expressed as pg/ml of PGE2 or PGEM. 
Human samples: 
Tissue sections of pancreatic adenocarcinoma (PDA) and normal pancreas were 
obtained from the NIH/NCI tissue repository (http://seer.cancer.gov/biospecimen). The 
serums of PC patients of different stages were also obtained from NCI.   
Mouse Tumor Samples: 
1X106 BxPC3 Neo and MUC1 cells were injected subcutaneously in each nude 
mice to grow BxPC3 Neo and MUC1 xenografted tumors. A month later, mice were 
sacrificed and tumors and other organs were harvested for IHC and for preparation of 
tumor lysate. PDA mice were sacrificed at between 16 weeks and 40 weeks to obtain 
KCKO and KCM tumors. Paraffin embedded blocks of formalin fixed tumor sections 
were made by the Histology Core at Mayo Clinic. 4 micron thick sections were prepared 
for immunohistochemical staining.  
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Immunohistochemistry:  
The tumor sections were treated with Dako antigen retrieval solution at 95°C for 
20-40 min followed by cooling it at RT for 20 min. To quench endogen us peroxidase, 
slides were rinsed, incubated for 10 minutes in methanol/2% H2O2 solution. Sections 
were washed, blocked in 5% normal bovine serum for 45 min, and incubated overnight at 
4°C with primary antibodies. Sections were incubated 1 h wit  appropriate secondary 
antibody, developed with a diaminobenzidine (DAB) substrate, counterstained with 
hematoxylin, and mounted with Permount. Primary antibodies used were: Armenian 
hamster anti-MUC1 cytoplasmic tail (CT) CT2 (1:50, own), goat anti-COX-2 (1:100; 
Santa Cruz Inc). Secondary antibodies were anti-hamster (1:250, Jackson Labs), and anti-
goat (1:100, Dako) IgGs conjugated to horseradish peroxidase. Immunopositivity was 
assessed using light microscopy and images taken at 20× magnific tion. 
Chromatin Immunoprecipitation (ChIP):  
Cells grown to near 80% confluence, were cross-linked with formaldehyde 
(Sigma) at room temperature for 10 min. Cross-linked chromatin prepared with a 
commercial ChIP assay kit (EZ-Magna ChIP; Millipore) was immunoprecipitated with 
normal Armenian hamster IgG (1:20) (Santa Cruz Biotechnology, CA, USA),  anti-
MUC1 CT antibody (CT2) (1:15) and anti-NF-kB (1:20) antibody. MUC1 CT binding 
site on Cox-2 gene promoter was amplified by PCR using the input DNA (2%) or DNA 
isolated from precipitated chromatin as templates and using primers flanking the 
promoter region -377/-175 bp upstream (ChIP region I) and +8320/+8550 bp downstream 
(ChIP region II) of transcription start site (TSS) of mouse Cox-2 gene (Fig. 3.11b, top 
panel) and -346/-118 bp upstream (ChIP region I) and -4053/3820 bp upstream (ChIP 
region II) of human COX-2 gene (Figure 3.11b, bottom panel). IgG was used as a 
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negative control for immunoprecipitation step and ChIP region II was used as a negative 
control for binding of MUC1 CT and NFkB to the promoter region. Sequence of the 
primers is available upon request. 
Semi-quantitative and quantitative RT-PCR:  
Total RNA was extracted from the cells by TRIzol (Invitrogen) according to the 
manufacturer‟s protocol. 1–β μg of the extracted RNA was used as template for semi-
quantitative RT-PCR reaction (Access quick RT-PCR kit, Promega, Madison, WI, USA) 
and real time RT- PCR (KAPA SYBR Fast One-step qRT-PCR kit). Sequence of the 
primers is available upon request. 
Cell growth by MTT assay:  
10 X 103 cells were plated in quadruplicate in normal growth medium in 96-well 
plates and were permitted to grow for 18 hours. Cells were left untreated or treated with 
Celecoxib (Pfizer, CN, USA) for 24 hours. Next, MTT (Biotium) solution was added (10 
ul/well) to cells, incubated for additional 3-4 hours. In the final step, media was removed, 
formazan was dissolved in DMSO (200ul/well) and the absorbance was read on an 
ELISA plate reader. 
Invasion assay:  
Cells were grown on culture dish and serum-starved for 18 h before plating for the 
invasion assay. In a 24 well plate, 50,000 cells in serum-free m dia with or without 
Celecoxib were plated over transwell inserts (BD Biosciences, San Jose, CA, USA) 
precoated with reduced growth factor matrigel (BD Biosciences, San Jose, CA, USA). 
Cells were allowed to invade through the matrix toward the serum supplemented media 
contained in the bottom chamber over a period of 36 h. Percent invasion was calculated 
as absorbance of samples/absorbance of controls*100. 
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Densitometric quantification of western blot analyses: For quantification of the 
bands of Western blot and semi-quantitative RT-PCR, densitometric analysis was 
performed using image analysis software (Image J) from the National Institutes of Health 
(Bethesda, MD).  
Statistical Analysis: Statistical analysis was performed with GraphPad software.  
3.3. Results  
 Human PDA sections express high levels of MUC1 and Cox-2 protein: 
 Overexpression of Cox-2 is frequently observed in pancreatic cancer. The 
objective of the study was to first analyze if Cox-2 is overexpressed in PDA and if so 
does its expression correlate with MUC1 overexpression. We performed IHC to 
determine the MUC1 and Cox-2 expression in human PDA sections and compared it with 
adjacent normal pancreas sections. All four human PDA sections stained strongly for 
both MUC1 and Cox-2 in comparison to the adjacent normal pancreas indicating that 
MUC1 and Cox-2 are overexpressed in PDA and there is a possible link between the 
coexpression of these two molecules in human PDA. (Figure 3.8A) We next analyzed the 
PGE2 levels in serum obtained from PDA patients diagnosed with stage 0 to stage 4 of 
PDA. We detected 63.8 pg/ml, 118 pg/ml, 148.8 pg/ml and 210 pg/ml of PGEM/ml of 
serum in stage 0, stage 2, stage 3 and stage 4 samples respectiv ly (Figure 3.8B). There 
was a 4 fold increase in the serum PGEM levels in tage 4 PDA patients compared to 
stage 0 PDA patients. Our data indicates that during the progression of human PDA, 
serum PGEM levels progressively increases in a stage dependent man er, implicating a 
possible role of Cox-2 in the progression of the disease. Similarly, there was a steady 
increase in levels of MUC1 in the same serum samples [119] (Appendix, figure 1).  
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 Cox-2 is overexpressed in PDA cell lines that endogenously express high 
levels of MUC1:  
 To validate our observation of positive correlation between MUC1 and Cox-
2 expression in human PDA, we examined a panel human PDA cell lines that express 
various levels of endogenous MUC1 and analyzed basal MUC1 and Cox-2 levels by 
western blot. HPAFII, HPAC, CFPAC and Capan-1 PDA cell lines express high levels of 
endogenous MUC1, whereas BxPC3, Hs766T, Capan-2 and MiaPaca-2 express low 
levels of endogenous MUC1 (Figure 3.9 A). We found that that MUC1 high HPAFII, 
HPAC, CFPAC and Capan-1 cells expressed higher levels of Cox-2 c mpared to MUC1 
low Hs766T, Capan-2 and Mia-Paca-2. However, BxPC3 cell line showed significantly 
high levels of Cox-2 expression inspite of having low levels of endogenous MUC1 
(Figure 3.9 A). This observation is similar to what has been reported before in a study 
where a panel of PDA cells lines were evaluated for endogenous Cox-2 levels and BxPC3 
was reported to be a very high Cox-2 expressing cell line [120]. This may be due to the 
fact that BxPC3 is known to have a normal ras proto-oncogene whil  all other cell lines 
have mutated ras [121]. Out of the eight human PDA cell lines that were included in the 
study, seven cell lines exhibited a positive correlation between MUC1 and Cox-2 
expression.  
 Overexpression of MUC1 augments Cox-2 expression and a simultaneous 
attenuation upon MUC1 downregulation:  
 We next performed a gain of function and loss of functio  study, to 
determine if Cox-2 gene expression is altered upon manipulation of MUC1 levels in the 
PDA cell lines. We found that BxPC3 and Panc02 cells stably transfected with full length 
MUC1 express 3.3 fold and 2.6 fold higher Cox-2 levels respectively n comparison to 
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BxPC3 and Panc02 cells stably transfected with the empty vector (Figure 3.9B, 
supplemental table 1). Similarly, mouse PDA cell line KCM cells that genetically express 
MUC1 express 3.9 fold higher Cox-2 compared to KCKO cells that are genetically null 
for MUC1 (Figure 3.9B, supplemental table 1). Next, we transiently knocked down 
MUC1 expression transiently using MUC1 specific siRNA in MUC1 high HPAFII and 
HPAC cell lines and evaluated the levels of Cox-2 by western blot. Following MUC1 
downregulation, we observed a 3.5 fold decrease in Cox-2 expression in HPAFII cells 
(Figure 3.9C, supplemental table 2) and a 5.8 fold decrease in th  Cox-2 expression in 
HPAC cells (Figure 3.9C, supplemental figure 2). Thus we observed that overexpression 
of MUC1 in PDA cells lines causes an increase in MUC1 expression and downregulation 
of MUC1 causes a decrease in MUC1 expression indicating that Cox-2 gene in PC is 
regulated by MUC1.  
 IHC was performed to compare MUC1 and Cox-2 expression between 
tumors from PDA mice that are null for MUC1 (KCKO) or express MUC1 (KCM). As 
expected, KCKO do not show any staining for MUC1 and expresses low levels of Cox-2, 
whereas, KCM tumors show strong membranous and cytoplasmic MUC1 staining and 
show abundant Cox-2 tissue expression. BxPC3 Neo and BxPC3 MUC1 xenografted 
tumors were also stained for MUC1 and Cox-2 expression. BxPC3.MUC1 tumors 
expressing high levels of MUC1 also show high Cox-2 expression in comparison to 
MUC1 low BxPC3 Neo tumors. 
 We performed IHC on mouse PDA tumors that are null for MUC1 (KCKO) 
or MUC1 positive (KCM) to evaluate the coexpression of MUC1 and Cox-2 insitu. 
KCKO tumors did not stain for MUC1 and showed low Cox-2 expr ssion as indicated by 
weak brown staining. In contrast KCM tumors showed high expression of both MUC1 
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and Cox-2, as indicated by the strong brown staining (Figure 3.10, left panel). Staining 
for Cox-2 and MUC1 xenografted tumors showed similar trend. As expected, MUC1 
high BxPC3MUC1 tumors showed higher expression of Cox-2 compared to MUC1 low 
BxPC3 Neo tumors (Figure 3.9, right panel).  
 MUC1 high PDA cells express high levels of Cox-2 mRNA:  
 We next evaluated the levels of Cox-2 mRNA in PDA cell lines expressing 
variable levels of MUC1. The steady state levels of Cox-2 mRNA was significantly 
higher in MUC1 positive Panc02 MUC1 and KCM cells compared to MUC1 low KCKO 
and Panc02 Neo cells (Figure 3.10A). We observed 2.14 fold higher Cox-2 mRNA in 
Panc02 MUC1 cells in comparison to Panc02 Neo cells by real time qPCR (Figure 
3.10B). A significant decrease (13.9 fold) in Cox-2 mRNA level was observed upon 
transient knockdown of MUC1 in HPAFII cells (Figure 3.10A). This data suggests that 
Cox-2 gene is upregulated in MUC1positive PDA cell lines.    
 MUC1 and NFkB colocalizes and binds to the promoter of the Cox-2 gene: 
 We next sought to investigate the molecular mechanism of MUC1 induced 
Cox-2 gene regulation. The 5‟UTR of human COX-2 gene contains a TATA box and 
several potential transcriptional regulatory elements such as CRE (59/53), NF-IL6 (-132/-
124) and NF-kB (-233/-214 and -448/-439) and mouse Cox-2 gene contains CRE-2 (-
438/-428), NF-kB (-400/-392), C/EBP (-136/-128) and AP-1 (-67/-62), that are essential 
for Cox-2 gene expression [122], [123] In colon cancer, NF-kB is important for 
transcriptional regulation of Cox-2 gene as indicated by attenuation of Cox-2 expression 
upon NFkB downregulation in colon cancer cells [124], [125]. Previously it was reported 
that MUC1 CT constitutively associates with NF-ҡB p65 subunit and prevent IkBα from 
binding to NF-ҡB p65. MUC1 also promotes the occupancy of NF-ҡB transcriptional 
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complex to the promoter of NF-ҡB p65 target gene Bcl-xL gene and thereby increases its 
expression [65]. Thus, we explored the possibility if MUC1 and NF-ҡB co-localizes to 
the promoter of the COX-2/Cox-2 gene and drives its expression.  
 We first evaluated the nuclear localization of MUC1 CT and NF-ҡB p65 in 
the human and mouse PDA cell lines under basal level. We obs rved presence of MUC1 
CT in the nucleus of Panc02 MUC1, KCM, HPAFII and HPAC cells andbsence of 
MUC1 CT in the nucleus of Panc02 Neo and KCKO cells (Figure 3.11A, top panel). We 
did not observe any significant difference in the levels of NF-ҡB p65 in the nucleus of 
MUC1 null KCKO, Panc02 Neo and MUC1 positive KCM and Pan02 MUC1 cells 
(Figure 3.11A). This data indicated that the nuclear localization of NF-ҡB p65 is not 
affected by the presence or absence of MUC1 in the cells. Thi  observation is in contrast 
to what has been reported before that downregulation of MUC1 in ZR-75-1 breast cancer 
cells cause a decline in the nuclear accumulation of NF-ҡB p65. This could be possibly 
because of differences in tumor origin. 
 We performed ChIP to examine the binding of MUC1 CT and NF-kB p65 to 
the promoter region of mouse and human Cox-2 gene.  We immunoprecipitated sheared 
chromatin using anti-p65 antibody and anti-MUC1 CT antibody. The immunoprecipitated 
chromatin was PCR amplified using primers design around the NF-kB response element 
in the promoter region of Cox-2 gene. In MUC1 positive KCM cells, we observed MUC1 
CT and NF-kB p65 binding to ChIP region I, containing the NFkB RE in the promoter 
region of Cox-2 gene. In contrast, in KCKO cells, in absence of MUC1, NF-kB p65 no 
longer binds to ChIP region I in the promoter region of Cox-2 gene (Figure 3.11C, left 
panel). We observed similar trend in Panc02 Neo and Panc02 MUC1 cells (Figure 3.7.B). 
Further analysis of HPAFII cells showed that increased occupancy of NF-kB p65 in the 
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ChIP region I of Cox-2 gene is associated with MUC1 CT. As a control, there was no 
detectable signal in the immunoprecipitates performed with nonimmune IgG (Fig. 3B). 
There was also no detectable MUC1 CT and NF-nB p65 occupancy in the control region 
(ChIP region II) downstream of the Cox-2 promoter (Fig. 3.11C, right panels). 
 Blocking Cox-2 activity by Celecoxib reduces proliferation a d invasion in 
PDA cells: 
 Among several factors that are known to augment proliferation nd invasive 
phenotype of cancer cells, Cox-2 is thought to be one of the key players. In colon, breast 
and PDA cells, Cox-2/PGE2 signaling axis promotes proliferation, survival and invasion 
[126], [127], [128]. In non-small cell lung cancer (NSCLC), Cox-2 promotes invasion 
through decreased production of CD44, MMP-2 and EP4 receptors [129]. Another study 
showed that in NSCLC, Cox-2 induces invasion by suppressing E-cadherin expression 
via transcriptional suppressor ZEB1[130]. Previously we and others have shown that 
overexpression of MUC1 increases the proliferative index and invasive potential of the 
PDA cells [58], [61], [62], [63], [131]. So, we hypothesized that MUC1 promotes 
proliferation and invasiveness in cancer cells through Cox-2. In this study, we inhibited 
Cox-2 activity in MUC1 high PDA cells with Celecoxib and analyzed if Cox-2 inhibition 
negatively affects growth and invasive potential of PDA cells.  
 We first treated MUC1 high and low PDA cell lines HPAFII, HPAC, KCM 
and KCKO with increasing concentration of Celecoxib and 24 hours later performed 
MTT assay to evaluate the growth arrest. At 50uM, 75uM and 100uM of Celecoxib, we 
observed 18.9%, 42.7% and 56.4% of growth arrest in HPAFII cells (Figure 3.12A.I.), 
and 16%, 47.1% and 59.6% of growth arrest in HPAC cells (Figure 3.12C.I). Similarly, 
in KCKO and KCM cells, we observed a similar dose dependent increase in growth arrest 
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upon blocking Cox-2 with Celecoxib. At 25uM, 50uM, 75 uM and 100 uM of Celecoxib, 
20%, 42.4%, 62.5% and 81.5% of growth arrest in KCKO cells and 15.5%, 29.7%,49.2% 
and 71% growth arrest in KCM cells was observed. However, in comparison to KCKO, 
KCM were more resistant to growth arrest, although Cox-2 was sufficiently blocked in 
both cell lines as indicated by the western (Figure 3.12C.II). This could be due to 
hyperactivation of the prosurvival pathway PI3K/Akt in KCM cells, which counteracts 
the growth inhibitory effect of Celecoxib [57]. Overall blocking Cox-2 activity caused a 
profound growth arrest in PDA cells, indicating that Cox-2 is important for the growth of 
these cells. However this inhibition of growth is independent of MUC1 expression as 
both MUC1-high and low expressing PDA cells responded to celecoxib. 
 We next evaluated the expression of Cox-2 and MUC1 protein upon 
Celecoxib treatment to a) determine the level of Cox-2 blocking and b) to analyze if 
MUC1 expression is affected upon inhibiting Cox-2 activity. In HPAFII, HPAC, KCKO 
and KCM cells, a gradual decrease in the Cox-2 protein is observed upon treatment of the 
cells with increasing of Celecoxib (Figure 3.12A.II, B.II and C.II). However, we did not 
observe the MUC1 levels to change upon blocking Cox-2 activity, ndicating an absence 
of feedback loop between Cox-2 and MUC1. They share a unidirectonal relationship, 
where Cox-2 gene is under MUC1 regulation and not the otherway around. Interestingly 
in HPAC cells, we observed a moderate increase in MUC1 expression upon exposure to 
Celecoxib (Figure 3.12 B.II).  
 We next evaluated the invasive potential of a panel of human PDA cell lines 
that express high levels of Cox-2. Mia-Paca-2 cell line, which is null for Cox-2 was 
included as a negative control. We found that HPAFII, HPAC and Mia-Paca-2 cells were 
13.5%, 10.85% and 11.8% invasive, whereas CFPAC was 24.6% invasive (Figure 
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3.13A). Thus, although HPAFII, HPAC and CFPAC cells express high endogenous 
MUC1 and Cox-2, their inherent invasive potential is different because the cohort of 
mutations in these cell lines is also different.  Next we treated CFPAC cells with 
Celecoxib, to determine if blocking Cox-2 activity attenuates its invasive potential. We 
observed a 2 fold decrease in the invasive potential of CFPA cells upon treatment with 
15uM and 30 uM of Celecoxib (Figure 3.13B), indicating that Cox-2 is important the 
invasiveness of the cell line. KCM cells which express higher levels of Cox-2 is 82% 
invasive in comparison to KCKO cells which is 60% invasive. 1.6 fold (51.6%) and 4.3 
fold (19.49%) decrease in the invasive potential of the KCM cells is observed upon 
treatment of the cells with 15uM and 30uM of Celecoxib. The invasive potential of KCM 
cells treated with 15uM of Celecoxib is equivalent to the invasive potential of KCKO 
cells, indicating that higher invasive potential in KCM cells is associated with Cox-2 
activity.   
3.4. Discussion 
Overexpression of MUC1 in pancreatic and in other solid tumors, and its 
implication in malignant tumor progression, has been described by various research 
groups. Importantly, it was demonstrated that MUC1 overexpression promotes invasion 
and proliferation of PDA cells [62], [63]. Hence, MUC1 has become an attractive 
molecular target for cancer therapy. In pancreatic cancer Cox-2 is frequently 
overexpressed which is associated with increased angiogenesis, immune suppression, 
tumor cell proliferation and invasion. However the relationship between these two 
molecules has never been studied before. Our study demonstrates for the first time that 
MUC1 is an important regulator of Cox-2 gene expression, which promotes proliferation 
or invasion in the PDA cells.  
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We demonstrate that the levels of COX-2 protein are increased in both primary 
human PDA and in PDA cell lines that express high levels of MUC1 (Figure 13.8). In 
both human and mouse PDA sections, COX-2 was overexpressed in tumors that 
expressed high levels of MUC1. The relationship between MUC1 and Cox-2 was 
effectively recapitulated in PDA cell lines, where we demonstrate that overexpression of 
MUC1 in MUC1 low cell lines leads to increase in Cox-2 mRNA and protein expression. 
Consequently, knockdown of MUC1 in MUC1 high PDA cell lines attenuates Cox-2 
mRNA and protein expression (Figure 13.9, 13.10). Interestingly, in BxPC3 cells a 
significant difference in Cox-2 expression was observed although there was no 
significant difference in the Cox-2 mRNA level, raising a possibility of post 
transcriptional regulation of Cox-2 by MUC1. The stability of Cox-2 mRNA is largely 
regulated by a complex network of Erk1/2, p38 MAPK and PI3K pathways [132]. Most 
of these signaling pathways are over activated in cancer cells that overexpress 
MUC1[57], [58], [61]. Thus the possibility that MUC1 increase Cox-2 expression 
posttranscriptionally in PDA cells cannot be overruled. Recently it was reported that 
downregulation of miR-143 in PDA cells increases the stability of Cox-2 mRNA leading 
to increased Cox-2 protein in PDA cells. MUC1 has been shown t  induce galectin-3 
expression in PDA cells via suppressing miR-322 expression and thereby stabilizing 
galectin-3 transcripts.  
In pursuit of elucidating the mechanism by which MUC1 regulates Cox-2 
expression, we analyzed occupancy of MUC1 and NF-kB to the promoter of Cox-2 
(PTGS1/Ptgs1) gene by ChIP assay. We found that MUC1 CT and NFkB binding to 
ChIP region I (within 1000bp upstream of TSS) in the 5‟UTR region of both mouse and 
human COX-2/Cox-2 gene. KCKO cells that are null for MUC1 did not show any binding 
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of MUC1 CT and NF-kB to the 5‟UTR of mouse Ptgs-2 gene (Figure 13.11). These cells 
display low Cox-2 mRNA level indicating that loss of MUC1 attenuates binding of NFkB 
to the promoter of Cox-2 gene and thereby affects the transcription of Ptgs-2 gene.  
 Lastly, we determine the biological significance of Cox-2 in the MUC1 high 
PDA cells by blocking the Cox-2 activity. We observed a dose dependent decrease in 
growth of HPAFII, HPAC, KCKO and KCM cells upon treatment with Celecoxib 
underscoring the importance of Cox-2 in proliferation of PDA cells (Figure 13.12). 
Interestingly, although KCKO cells expressed less Cox-2 compared to KCM, they were 
more susceptible to growth inhibition by Celecoxib compared to KCM. This could due to 
the fact that Celecoxib not only inhibits Cox-2 activity, but also modulates cell survival 
pathways and other cellular responses. A study showed that the n itumor effect of Cox-2 
is not entirely contingent upon its ability to inhibit Cox-2 activity but  rather owing to its 
ability to initiate ER stress [133]. It could be possible that in KCKO cells Celecoxib 
initiates ER stress which is counteracted better in KCM cells.  
On analyzing the basal level of invasive potential of HPAFII, HPAC, CFPAC and 
Mia-Paca-2 cell lines, we found that only CFPAC cell line was invasive and treatment 
with Celecoxib resulted in decrease in their invasive potential (F gure 3.13). Thus, Cox-2 
is critical for proliferation of HPAFII, HPAC, KCKO and KCM cells, but not for their 
invasive potential. In contrast, Cox-2 is important for both invasion and proliferation of 
CFPAC cells.  Thus, although Cox-2 is overexpressed in MUC1 high PDA cells, the 
biological effect of Cox-2 may not be the same in all MUC1 high cell lines. The variation 
in the biological effect of Cox-2 could be due to differenc  in the expression profile of 
the EP receptors in the cells lines, and the subsequent engagement of one or more of the 
signaling pathways downstream of Cox-2/PGE2 signaling axis. Nonetheless, the 
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significance of Cox-2 overexpression by the MUC1 high cells cannot be underrated as
Cox-2 not only affects tumor cells but also other cellular components in the tumor 
microenvironment. For example, it has been reported that Cox-2 causes suppress 
activation of immune response against tumor by recruiting MDSC in the tumor 
microenvironment. Moreover, Cox-2 is known to regulate VEGF expression and promote 
angiogenesis [134], [135]. Previously we and others reported that MUC1 modulates  
expression of VEGF in pancreatic and breast cancer cells [81] [62].  
In conclusion, MUC1 is an important mediator of tumor growth, metastasis and 
angiogenesis, and also functions as positive regulator of COX-2 expression in PDA. 
Hence, targeting the cytoplasmic tail of MUC1 using MUC1 inhibitor GO-203, which 
blocks the CQC motif and prevents MUC1 dimerization, may be a promising approach 
for the treatment of patients with advanced and/or metastatic pancreatic cancer. 
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Figure 3.1. Biosynthesis of Prostaglandin from Arachidonic ac d [114]. 
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Figure 3.2.Biosynthetic pathway of prostaglandins [136]. 
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Figure 3.3: Signaling pathways activated by the EP receptors for PGE2: PGE2 binds to G-
protein couples EP receptors and activates the downstream signaling cascade. There are 
four types of EP receptors - EP1, EP2, EP3 and EP4.The tissue expr ssion of the 
receptors are different and such the biological effect of PG is tissue specific [137].  
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Figure 3.4: Three dimensional structure of the Cox enzyme: The Cox enzyme has 4 
distinct domains, EGF like domain, membrane binding domain, peroxidase (POX) active 
site and cyclooxygenase (COX) active site [138]. 
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Figure 3.5: Selective binding of Celecoxib to the active sit  of Cox-2: The Cox channel in 
Cox-1 is wide enough to allow AA to access the active site of the enzyme, but excludes 
the entry of bulky Celecoxib. In contrast, Cox-2 has a wider Cox channel, which allows 
the bulky Celecoxib to enter with ease. In addition, the presence of side pocket created by 
Val 523 allows Celecoxib to effectively bind to the active sit of Cox-2 [153] 
 
 
 
Figure 3.6: Chemical structure of Cox-2 specific inhibitor Celecoxib [139]. 
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Figure 3.7: A stage dependent increase in the MUC1 and Cox-2 expression in PDA. MUC1 
mouse: Tumor sections representing different stages of PDA were obtained from 
PDA.MUC1 (KCM) mice and were analyzed for MUC1 expression usi g CT2 antibody and 
Cox-2 using anti-Cox-2 antibody [118].  
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Figure 3.8: Expression of MUC1 and COX-2 in human pancreatic adenocarcinoma 
sections and PGE2 in the patient serum: A. IHC was performed to compare MUC1 and 
Cox-2 expression between the human PDA sections and its adjacent normal pancreas. 
Morphologically normal pancreas section shows low apical membranous MUC1 staining 
and lack of Cox-2 expression. Metastatic PDA samples show strong membranous and 
cytoplasmic MUC1 staining and show abundant Cox-2 in tumor cells. B. Serum PGE2 
levels from pancreatic cancer patients were assessed by PGE2 metabolite (PGEM) 
ELISA kit. An average of 5 patient samples have been shown here. One way ANOVA 
was performed to determine the statistical significance between the samples, ***p = 
0.0005. 
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Figure 3.9: Positive correlation between MUC1 and Cox-2 expression in human cell lines 
(in vitro) and mouse PDA sections. A. Levels of MUC1 and Cox-2 protein in a panel of 
human PDA cell lines were evaluated by western blot using anti MUC1 antibody CT2 
and anti-Cox-2 antibody respectively. 60ug of protein was loaded for SDS-PAGE. β-actin 
was used as loading control. B. Levels of MUC1 and Cox-2 protein in cell lines 
overexpressing MUC1was evaluated and compared with low MUC1 counterparts. 35 ug 
of protein was subjected to SDS-PAGE. C. ox-2 expression was evaluated in cells 
following endogenous MUC1 knock down using MUC1 siRNA. Cox-2 and MUC1 levels 
were analyzed by western. 60ug of protein was loaded for SDS-PAGE. D. IHC was 
performed to compare MUC1 and Cox-2 expression between Muc1 null tumors (KCKO) 
and MUC1 positive tumors (KCM). BxPC3 Neo and BxPC3 MUC1 xenografted tumors 
were stained for MUC1 and Cox-2 expression. KCM and BxPC3.MUC1 tumors showed 
high levels of Cox-2 in comparison to MUC1 low KCKO and BxPC3 Neo tumors. 
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Figure 3.10:  MUC1-positive PDA cell lines express elevated levels of Cox-2 gene in 
vitro.A. Total mRNA from PDA cell lines were isolated using TRIzol and the basal levels 
of Cox-2 mRNA were determined using semi-quantitative one step RT-PCR kit. B. 
Panc02 Neo and MUC1 Cox-2 mRNA was evaluated by real time RT-PCR. 
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Figure 3.11: MUC1 and NF-kB binds to the upstream promoter region of Cox-2 gene: A. 
Whole cell lysate from a panel of human PDA cell lines were immunoblotted to determine 
the constitutive NFkB status. β-actin was used as a loading control for SDS-PAGE. B. 
Schematic representation of the promoter region with its putative DNA binding elements in 
mouse and human Cox-2 gene. C. Sheared chromatin was immunoprecipitated using anti-
MUC1 CT antibody CT2 and anti-NFkB antibody. The immunopreci itated chromatin was 
PCR amplified.  
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Figure 3.12: Selective inhibition of Cox-2 with Celecoxib attenuates the growth of the of 
PDA cell lines: AI, BI and CI: Equal number of cells (4000 - 10,000) plated in 96 well 
plate were grown overnight. After 18 hours, cells were treated with or without the 
indicated concentration of Celecoxib and control DMSO for 24 hours. MTT assay was 
performed to determine the growth inhibition following Celecoxib treatment. Significant 
differences in growth in each cell line and between KCKO and KCM at varying 
concentrations of the Celecoxib is shown as p-values (n=8) (*p<0.1, **p<0.01, *** 
p<0.001). AII, BII and CII: Cells grown overnight in a 6 well plate were left untreated or 
treated with indicated concentration of Celecoxib for 24 hours. Cell lysate were prepared 
and were subjected to immunoblotting. The membrane was probed with anti-MUC1 
antibody (CT2), anti-Cox-2 and anti-β actin antibody to determine the MUC1, Cox-2 and 
β-actin levels respectively.   
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Figure 3.13: Selective inhibition of Cox-2 with Celecoxib attenuates invasive potential of 
the invasive PDA cell lines: Cells grown on culture dish were serum-starved for 18 h before 
plating for the invasion assay. In a 24 well plate, 50,000 cells in serum-free media with or 
without Celecoxib were plated over transwell inserts (BD Biosciences, San Jose, CA, USA) 
precoated with reduced growth factor matrigel (BD Biosciences, San Jose, CA, USA). Cells 
were allowed to invade through the matrix toward the serum supplemented media contained 
in the bottom chamber over a period of 36 h. Percent invasion was calculated as absorbance 
of samples/absorbance of controls*100. 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 4: MUC1 REGULATES THE SWITCH IN TGF-β1 FUNCTIONING FROM 
TUMOR SUPPRESSOR TO TUMOR PROMOTER 
 
4.1. Introduction  
Transforming growth factor‑β (TGF-β) is a pleotropic cytokine with dual 
functionality. In normal epithelial cells, TGF-β causes growth arrest and apoptosis, which 
constitutes the tumor suppressive function of TGF-β signaling. Additionally, TGF-β can 
trigger proliferation and EMT (epithelial to mesenchymal trnsition) in normal epithelial 
cells, a physiological process crucial for organogenesis and development. This constitutes 
the tumor promoting arm of TGF-β, as in cancer cells this signaling axis of TGF-β 
becomes dominant and promotes invasion and metastasis of cancer [140], [141], [142]. 
Thus it can function both as a tumor suppressor and a tumor promoter. In normal 
epithelial cells, the tumor suppressive arm of TGF-β signaling is dominant. At early 
stages of tumorigenesis, when the tumor is still benign, it acts directly on the cancer cell 
to suppress tumor growth [143]. However, as the cancer progresses, the tumor 
suppressive arm of TGF-β signaling is lost and the tumor promoting arm of TGF-β 
signaling gains dominance[144], [145], [146], thus changing from a tumor suprresor to a 
tumor promoter. The mechanism(s) underlying the switch functio al switch of TGF-β is 
not definitively known. 
TGF-β1, TGF-ββ and TGF-βγ are the three isoforms of TGF-β. TGF-β1 is the 
most abundant and universally expressed isoform. Activation of TGF-βRII involves 
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binding of TGF-β1 to TGF-βRII and its subseuqent autophosphorylation. Activated TGF-
βRII in turn phosphorylates TGF-βRI, which in turn activates a class of signaling proteins 
known as Smads. Smads are the principle effector molecules of the canonical TGF-β 
signaling pathway. TGF-βRII activates Smadβ/γ, which upon activation, binds to an 
additional protein, SMAD4 or co-Smad, and translocates to the nucleus. Within the 
nucleus, this complex acts as a transcription factor where the protein that binds to DNA 
and contributes to the activation for various genes, thus riggering apoptosis (Figure 4.1) 
[147]. However, in recent years, a number of additional pathw ys have been discovered 
that potentially regulate the different cellular responses to TGF-β. Some of these non-
canonical signaling pathways are PI3K/Akt, Erk1/2, JNK, p38 MAPK pathw ys [144], 
[148], [149]. Integration of the canonical and non-canonical signaling pathways 
contributes to the paradoxical role of TGF-β1 signaling. In transformed cells, aberrations 
in either canonical or non-canonical signaling cascade can result in a loss of tumor 
suppressive but gain in the tumor promoting function of TGF-β1[150]. Some of the 
anomalies frequently observed in the canonical pathway are downregulation of TGF-β 
receptors, upregulation of I-Smads (inhibitors of TGF-β signaling cascade) and mutation 
or deletion of Co-Smad (Smad-4/ DPC4) [144], [150]. Overactivation of the non-
canonical TGF-β signaling pathways such as PIγK/Akt, Erk1/β and pγ8MAPK pathways 
have also been reported in transformed cells. 
However, as the tumor progresses, genetic and/or biomedical changes allow TGF-
β1 to stimulate tumor progression by its pleiotropic activities on the cancer cells. TGF-β1 
stimulating invasion and metastasis might be of greater clinical consequence than its 
tumor-suppressive role, as the majority of human tumors retain a functional TGF-β1 
signaling pathway [143]. TGF-β1 induces epithelial-to-mesenchymal transition (EMT), a 
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process by which epithelial cells lose their cell polarity and cell-cell adhesion, and gain 
migratory and invasive properties to become mesenchymal cells. TGF-β1-induced EMT 
leads to migration and invasion of local epithelial cells. This could be through the 
extracellular signal-regulated kinases (ERK) pathway, a chain of proteins in the cell that 
communicates a signal from a receptor on the surface of the cell to the nucleus of the cell. 
This pathway communicates by adding phosphate groups to a neighborin  protein, which 
acts as an "on" or "off” switch. This results in an escape of apoptotic fates of these cells, 
and this is important for tumor metastasis [141]. Strategies for chemotherapy targeting 
functional TGF-β1 must consider its bifunctional action and attempt more specific 
targeting to inhibit tumor promoting TGF-β1 signaling pathway, thus preventing 
outgrowth and metastasis [143]. 
Previous research has shown that like TGF-β1, MUC1 plays a major role in EMT 
as well as drug resistance, invasion, and metastasis in pancreatic cancer [57], [62]. 
Therefore, the goals of this research project include det rmining the differential effects of 
TGF-β1 induced EMT in MUC1+ and MUC1- cells, and determining the differential 
effects of TGF-β1 induced apoptosis in MUC1+ and MUC1-. It is hypothesized that 
upregulation of MUC1 and signaling through its cytoplasmic tail supports TGF-β1-
induced EMT and invasion and inhibits TGF-β1-induced apoptosis (Figure. 4.2).  
4.2 Materials and Methods 
Cell Culture:  
All experiments were performed in vitro with a panel of human (CFPAC, HPAC, 
HPAF II, Capan 1, Panc 1, Mia Paca 2, SU86.86, BxPC3 MUC1, BxPC3 Neo) and  
mouse (KCM, KCKO,  Panc o2 MUC1, Panc o2 Neo)  PDA cell lines. All cells lines are 
established cell lines from the American Type Culture Collection (ATCC) and derive 
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from pancreatic ductal adenocarcinoma. All cells were cultured in 10 cm plates in an 
incubator at 37⁰C. Cells were split and fed with C-DMEM media every other day or 
when the cells became, at most, eighty percent confluent. 
           Western blots:  
Equal quantities (determined from BCA Assay) of cell lysates w re loaded on 
SDS-PAGE gels. When developing the loading buffer and gel for the Western Blotting, 
8%, 10%, and 12% gels were used. These gels consisted of various mounts of DI H20, 
30% Acrylamide, 1.5M Tris pH 8.8, 10% SDS, 10% APS, and TEMED. After pou ing 
the gel, the samples were added to the gel, and the protein was transferred through the 6 
processes of gel electrophoresis, a method for separation and analysis of macromolecules 
and their fragments, based on their size and charge (AbCam, 2012). The molecular 
weights of TGF-βR1 (56 kDa), TGF-β Rβ (64 kDA), and β-actin (42 kDa) were taken not 
of, and they were analyzed using various primary antibodies (1:1000 dilution) and 
secondary antibodies (1:2000 dilution).  
Invasion assay:  
Cells were serum starved for 18 hours before plati8ng for invasion assay. 30,000 
cells were plated on growth factor reduced matrigel coated inserts and were left untreated 
or treated with 10ng/ml of TGFβ1. The cells were allowed to invade through the matrix 
towards the serum containing media in the bottom chamber for 48 hours. 
Annexin – V staining:  
Serum starved cells were treated with 10ng/ml of TGF-β1 for 48hours. Apoptosis 
was measured by via Annexin V / 7AAD flow cytometry staining. Annexin V binds with
high affinity to membrane phospholipid phospha-tidylserin  (PS) which translocates from 
the inner to the outer leaflet of the plasma membrane in apoptotic cells. Staining with 
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Annexin V-FITC is typically used in conjunction with a live/dea dye 7-Amino-
Actinomycin (7-AAD) to allow the identification of early apoptotic cells (7-AAD 
negative, Annexin V-FITC positive) from dead cells (7-AAD positive, AnnexinV-FITC 
positive). Viable cells with intact membranes exclude 7-AAD, whereas the membranes of 
dead and damaged cells are permeable to 7-AAD. 
4.3. Results 
We wanted to first investigate if there is any correlation between expression of 
MUC1, TGF-β receptors and TGFβ1 in human PDA cell lines. We analyzed the levels of 
MUC1, TGF-β RI and TGF-β RII in a panel of human PDA cell lines expressing variable 
levels of MUC1 by western blot. Panc1, MiaPaca2, and SU86.86 cells, which express 
low levels of endogenous MUC1 also express high levels of TGF-β RI and negligible 
levels of TGF-βRII (Figure 4.3a). Whereas, CFPAC, HPAC and HPAF II cells, which 
express high levels of endogenous MUC1 express high levels of TGF-β RII and low 
levels of TGF-βRI (Figure 4.3a). Similarly we observed that BxPC3 MUC1 cells which 
express high levels of MUC1 also express higher levels of TGF-βRII but lower levels of 
TGF-β RI in comparison to BxPC3 Neo cells. The data is indicative of a positive 
relationship between MUC1 and TGF-βII expression and an inverse relationship between 
MUC1 and TGF-βRI expression.  
  TGF-β1 is a known inducer of EMT and invasion in pancreatic cancer and 
since MUC1-expressing PDA cells undergo EMT and are highly invasive as compared to 
MUC1-null cells, we first examined if TGF-β1-induced invasion is dependent upon 
MUC1 expression. We found that MUC1-positive cells became more invasive upon 
TGF-β1 stimulation compared to MUC1-null cells. This suggests that MUC1 facilities 
TGF-β1 mediated EMT and signaling (Figure. 4.4a).  Whether this is due to the 
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differential expression of the TGF-βRI and TGF-βRII levels in these cells is not yet 
known. 
In normal epithelial cells, TGF-β1 induces apoptosis. However, in transformed 
cells, the TGF-β1 mediated apoptosis is abrogated. It has also been demonstrated that 
MUC1 expression abrogates the intrinsic apoptotic pathway. Therefor , we wanted to 
know if MUC1 has the ability to modulate TGF-β1 mediated apoptosis in MUC1 
expressing PDA cells. To determine the effect of MUC1 expression on TGF-β1 induced 
apoptosis, we performed Annexin V/7AAD staining and flow cytometry. We found that 
MUC1-positive cells resisted apoptosis upon TGF-β1 stimulation compared to MUC1-
null cells (Figure 4.4b).  To further validate that the differences are indeed due to MUC1 
expression, we first examined the basal level production of TGF-β1 by ELISA. We 
observed elevated levels of TGFβ1 in the culture supernatants of BxPC3 MUC1 cells in 
comparison to BxPC3 Neo cells at 6, 12 and 24 hour time points. However, at 48 hours, 
no significant difference in the levels of TGF-β1 was noted between BxPC3 Neo and 
MUC1 cells (Figure 4.4c). This could be due to accumulation of TGF-β1in the media of 
BxPC3 Neo cells that are not internalized for signaling purposes.  
We next wanted to investigate if the differential effect of TGF-β1 on MUC1 
positive and negative PDA cells stemmed from the differential activation of the TGFβ 
signaling pathways, especially since the TGF-βRI and TGF-βRII levels were significantly 
altered in MUC1 high and low cells. We analyzed the activation of Erk1/2 and 
Smad2/3pathways which represents the respective non-canonical a d canonical signaling 
axis of TGFβ signaling pathways. We assessed the kinase activity of the receptors by 
evaluating the phosphorylation of Smads and Erk1/2 following TGF-β1 stimulation. We 
observed significant phosphorylation of Smad2/3 at 30 minutes following TGF-β1 
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stimulation in both BxPC3 MUC1 and BxPC3 Neo cells. However, there was no 
difference in the levels of the phosphorylated Smad2/3 between the MUC1-positive and 
MUC1-null BxPC3 cell lines (Figure 4.5a). Interestingly, we observed elevated levels of 
phosphorylated Erk1/2 at 15 minutes and the consecutive time points following TGF-β1 
stimulation in MUC1 positive PDA cells compared to MUC1 null PDA cells (Figure 
4.5b). Note that BxPC3 MUC1 cells have inherently higher phospho Erk1/2 levels 
compared to Neo cells. Together, these data indicates that the difference in invasiveness 
and apoptotic response of MUC1 positive and negative PDA cells could be caused due to 
the difference in the expression of the TGF-β receptors and activation of the downstream 
Erk1/2 signaling cascades.  
4.4. Discussion 
 So far data indicates that MUC1 plays a role in switch of TGF-β1 function from a 
tumor suppressor to a tumor promoter. The negative correlation between MUC1 and 
TGF-β1 RI levels underscores that MUC1 could play a role in blocking TGF-β1-induced 
apoptosis because the phosphorylation of TGF-β1 RI leads to activation of proapototic 
pathway via Smad. Based on these results, if MUC1 is up regulat d, then TGF-β1 RI is 
down regulated, thus the apoptotic signaling pathway is not initiated. Also, the positive 
correlation between MUC1 and TGF-β1 RII with CFPAC, HPAC, and HPAF II is 
significant because the up regulation of TGF-β1 RII and down regulation of TGF-β1 RI 
indicates that TGF-β1-induced EMT may be occurring.  
 This study gives us the basis of a screening tool to predict whe her inhibition of 
TGF-β1 would be an effective treatment for a particular patient with pancreatic 
adenocarcinoma. This tool can be used to prevent patients from getting false treatment. If 
MUC1 is not expressed, then TGF-β1 inhibition would not be suggested because it would 
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be blocking TGF-β1 functioning as a tumor suppressor. If MUC1 is expressed, then TGF-
β1 inhibition would be suggested because this this expression leads to TGF-β1-induced-
EMT, which needs to be blocked. Not only does this study open u  a whole new field of 
study using TGF-β1 targeting as an effective treatment, but this study can also take us 
one step closer to understanding pancreatic cancer and cancers i  general. 
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Figures 4.5 
 
Figure 4.1: Canonical and non-canonical signaling pathways of TGF-β: Divergent TGF-β 
signaling pathways induce transcriptional regulation through SMAD pathway and induce 
invasion and metastasis through epithelial-to-mesenchymal transition (EMT) pathway 
[151]. 
 
 
 
Figure 4.2:  Hypothesis: The cytoplasmic tail of MUC1 supports TGF-β1- induced 
EMT and invasion and inhibits TGF-β1-induced apoptosis 
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Figure.4.3: Expression of TGF-β receptors in PDA cell lines: (a) A panel of human cell 
lines were tested for TGF-β RI, TGF-β RII, MUC1 expression by western blot. (b) 
BxPC3 Neo, MUC1 and Y0 cell lines were tested for expression of TGF-β RI, TGF-β 
RII, MUC1 by western blot. Β-acting was used as a loading control. (c) 0.25*106 0.4*106 
, 0.55*106 and  0.7*106 cells were plated in 6 well plates for the supernatant to be 
collected at 48hours, 24 hours,12 hours and 6 hours respectively. Whole cell lysates were 
prepared from the cells for BCA assay. The level of TGF-β1 secreted by BxPCγ Neo, 
MUC1 and Y0 cells were determined by analyzing the cell culture s p rnatant by ELISA. 
The results are represented as pg of TGF-β1 per ml of the cell culture supernatant. The 
levels of TGF-β1 were normalized to the whole cell lysates. 
 
 
 
 
 
 
 
112 
 
 
 
 
Figure 4.4: Differential effect of TGF-β1 on the human PDA cell line BxPC3 in absence 
and presence of MUC1:  (a) Cells were serum starved for 18 hours before plati8ng for 
invasion assay. 30,000 cells were plated on growth factor reduced matrigel coated inserts 
and were left untreated or treated with 10ng/ml of TGFβ1. The cells were allowed to 
invade through the matrix towards the serum containing media in the bottom chamber for 
48 hours. (b) 30,000 cells were plated in a 24 well plate and were serum starved 
overnight. Next day, cells were treated with 10ng/ml of TGF-β1 for 48 hours and were 
stained with Annexin V apoptosis kit to determine the level of apoptosis. 
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Figure 4.5: Preferential activation of the non-canonical TGF-β pathway-Erk1/2 in 
response to TGF-β1 in BxPC3 MUC1 cells: (a) 0.5*106 cells were plated in a 24 well 
plate and were serum starved for 6 hours. Cells were treated with 10ng/ml of TGF-β1 for 
indicated time points and were harvested following treatmn  to prepare whole cell 
lysates. Phosphor-Smad2/3, total Smad, phosphor Erk1/2 and total Erk1/2 were 
determined by western blot. 
 
 
 
            
              
  
(a) 
(b) 
 
 
 
 
 CHAPTER 5: OVERALL CONCLUSION AND FUTURE DIRECTIONS 
The aim of my PhD dissertation was to study the mechanistic role of MUC1 in 
conferring drug resistance, invasion and proliferation in PDA cells. Chapter 2 of my 
dissertation illustrates MUC1 induced drug resistance in PDA cells due to upregulation of 
ABC transporters. Previously, MUC1 has been implicated for attenuated sensitivity to 
chemotherapeutic drug cisplatin in colon cancer cells. The report stated that the 
cytoplasmic tail of MUC1 translocates to mitochondria where it interferes with the 
release of pro-apoptogenic factors and prevents induction of apoptosis. This accounts for 
the reduced sensitivity of the colon cancer cells to cisplatin [106]. Pancreatic cancer is a 
lethal disease and responds poorly to the chemotherapeutic dr gs. Here, we demonstrate 
that MUC1 upregulates MDR genes, which encodes for ABC transporters and it leads to 
reduced sensitivity of the PDA cells to anticancer drugs etoposide and gemcitabine. W 
observed overexpression of four ABC transporters, MRP1, MRP3, MRP5 and P-gp in 
MUC1 high PDA cells, and our investigation further focused on the ABC transporter 
MRP1. The mechanism of regulation of MRP3, MRP-5 and P-gp gene expression and 
their contribution towards increased drug resistance in PDA cells remains to be 
evaluated. Further, it would also be interesting to determin  if MUC1 downregulates the 
nucleotide transporters (NTs) in PDA cells, the lack of which has largely been implicated 
for reduced uptake of gemcitabine by cancer cells and hence reduced sensitivity to the 
drug [152].   
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In recent years, cancer stem cells have gained considerable attention, as the cancer 
stem cells contribute partly to the high drug resistance and metastasis associated with 
pancreatic cancer. Thus, an understanding of the molecular mechanism of drug resistance 
and metastasis with respect to cancer stem cells is of utmost importance.  Studies have 
shown that cancer stem cells display overexpression of ABC transporters, especially P-
gp, MRP1 and ABCG2 [153]. Our research group demonstrated recently that MUC1 is 
expressed in pancreatic cancer stem cells [119]. It would be interesting to determine if 
MUC1 similarly upregulates the ABC transporters and contributes to the drug resistant 
phenotype in cancer stem cells. The insights gained from such tudies can be used for 
designing therapies to combat the ABC transporters mediated drug resistance in cancer 
cells, including the highly resistant pancreatic cancer stem c ll population, with an 
overall aim to improve the chemotherapy outcomes in pancre ti  cancer patients.  
The second section of my dissertation aimed to investigate if MUC1 in PDA 
regulates a pro-inflammatory enzyme Cox-2, since high Cox-2 expression in cancer cells 
is known to be associated with increased drug resistance, giogenesis, and invasion. 
Previously our research group demonstrated a stage dependent increase in Cox-2 
expression in PDA.MUC1 tumors (KCM) which was absent in MUC1-null tumors. This 
was the first report which provided a direct correlation betwe n MUC1 and Cox-2 
expression in PC.  However, it was not studied in depth and it was not known if indeed 
MUC1 regulates Cox-2 expression and function in PC, and if so how. So, in the second 
part of my PhD thesis work, I addressed these questions. I studied the correlation between 
MUC1 and Cox-2 gene expression and also investigated the mechanism by which MUC1 
regulates Cox-2 gene expression in PDA cells. Here, we report that MUC1 increases 
Cox-2 expression in PDA cells, which bestows the cancer cells with growth and invasion 
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advantage. The study mainly focused on the transcriptional regulation of Cox-2 gene 
expression by MUC1. We demonstrate that MUC1 cytoplasmic tail promotes the 
occupancy of NFkB in the promoter of Cox-2 gene and thereby increases Cox-2 gene 
expression. The expression of Cox-2 gene is also largely regulated by a post-
transcriptional mechanism. A recent report demonstrated that downregulation of  miR-
143 reduces stability of Cox-2 mRNA which leads to overexpression of Cox-2 in PDA 
cells [154]. Another report stated that miR-301 is upregulated in PDA cells which causes 
constitutive activation of NFkB via downregulating the exprssion of NFkB repressing 
factor (Nkrf), causing augmentation in expression of several NF-kB target genes, 
including Cox-2 [155]. It would be interesting to determine if MUC1 regulates 
expression of these miRNAs or yet some newly undiscovered ones that regulate Cox-2 
gene expression in cancer cells by a post-transcription mechanism. To date only one 
research article has been published that demonstrates the potential role of MUC1 as a 
post-transcriptional regulator of its target gene [156]. A whole new exciting path remains 
unexplored which will unveil the role of MUC1 in post-transcriptional regulation of its 
target genes. 
The third part of my thesis involved studying the effect of MUC1 on TGF-β1 
signaling cascade. We have preliminary data which indicates that the presence or absence 
of MUC1 in the PDA cells acts as a decisive factor that governs TGF-β1 functions as a 
tumor promoter or tumor suppressor, respectively. We observed increased TGF-βRII 
expression in MUC1 positive BxPC3 cells and also increased activation of Erk1/2 
pathway. Currently, the causes of TGF-β1 functioning switch remains to be established. 
We speculate it could be caused by differential expression of TGFβ receptors and the 
downstream signaling cascade. A study showed that in breast cancer cells, intergrinβ 
117 
 
physically interacts with TGF-βRII via c-Src, which phosphorylates Y284 of TGF-βRII 
both in vitro and in vivo, and causes activation of p38 MAPK pathway. MUC1 CT has
been shown to physically associate with c-Src at YEKV motif (6th tyrosine residue).  
Thus, it would be interesting to determine if MUC1 activates  TGF-βRII and downstream 
signaling cascades p38 MAPK or Erk1/2 pathway via c-Src. We have preliminary data 
that suggests that c-Src is important for TGF-β1 mediated activation of Erk1/β pathway, 
as blocking c-Src with the c-Src inhibitor PP2 failed to activate Erk1/2 pathway upon 
TGF-β1 stimulation. However, whether TGF-βRII is at all required for c-Src mediated 
Erk1/2 activation remains unclear. Another intriguing aspect was the equal activation of 
the canonical Smad pathway in both MUC1 null and MUC1 positive cells. Although the 
expression profile of TGF-βRI and TGF-βRII is opposite in MUC1 null and MUC1 
positive cells, the activation status of the Smad pathw y seems to be independent of the 
receptor expression profile. Thus, MUC1 may interfere with TGFβ signaling downstream 
of the receptors in such a way that it blocks Smad proteins mediated apoptosis but 
promotes Erk1/2 pathway mediated invasion. 
Several scientific studies have demonstrated that the yrosine residues of MUC1 
CT possess critical signaling roles that augment proliferaton, invasion and resistance to 
apoptosis in cancer cells. Our research group demonstrated that MUC1 overexpression 
induces EMT in PDA cells and removal of all seven tyrosine residues of MUC1 CT 
(MUC1 Y0) abates the invasive potential of the PDA cells. However, absence of the 
tyrosine residues in MUC1 CT (MUC1 Y0) does not diminish MUC1 induced mdr genes 
expression or chemoresistance of the PDA cells, indicating that the tyrosine residues of 
MUC1 CT are important with respect to EMT, but not for the chemotherapeutic 
resistance against anti-cancer drugs (Figure 5.1a,b). In MUC1 Y0, although all the 
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tyrosine residues are missing, it still retains the CQC motif, which is critical for MUC1 
dimerization and nuclear translocation [157]. Thus, in MUC1 Y0, we observe MUC1 CT 
to translocate to the nucleus, bind to the promoter of ABCC1 gene and upregulates its 
expression (Figure 5.1c). 
Interestingly, when we investigated the importance of the tyrosine residues of 
MUC1 CT on the Cox-2 gene expression, we found that BxPC3 cells expressing MUC1 
Y0 expressed lower level of Cox-2 protein in comparison to BxPC3 MUC1. However, 
there was no significant difference in the Cox-2 mRNA levels between BxPC3 MUC1 
and BxPC3 Y0. Ekr1/2, p38 MAPK pathways have been implicated in the post 
transcriptional regulation of Cox-2 gene. We and others have observed that MUC1 
overexpression causes hyperactivation of the Erk1/2 pathway which is reversed upon 
removal of the tyrosine residues (MUC1 Y0). Thus, the decreased Cox-2 levels in BxPC3 
Y0 cells might be due to reduced activation of Erk1/2 pathway in MUC1 Y0 cells. 
Therefore, the manifestations of oncogenic properties of MUC1 are not just restricted to 
signaling through its tyrosine residues, but also through other yet unidentified motifs 
which regulates its transcriptional ability.  
Based on the current knowledge about MUC1 and its oncogenic role in pancreatic 
cancer, the cytoplasmic tail of MUC1 presents an attractive drugable target. Small 
molecule inhibitors targeting MUC1 CT can be used in combinatio  with chemotherapy 
to increase the sensitivity of PDA cells to chemotherap utic drugs. In addition, 
proliferation and invasion of PDA cells can also be counteracted upon targeting MUC1 
CT. A peptide based inhibitor GO-203, has been designed against the CQC motif of 
MUC1, which prevents MUC1 dimerization and nuclear translocati n [158]. Currently 
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GO-203 is at phase I clinical trial, where the inhibitor is being tested for optimal dosage, 
toxicity, route of administration and its effect on tumor regression [159].  
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Figure 5.1. The functional role of full length MUC1 in coxtemt of drug resistance is not 
attenuated upon removal of the tyrosine residues.(a) Difference in H3 thymidine uptake in 
BxPC3 Neo, MUC1 and Y0 cells following 24 hours treatment with etoposide. 
Significant differences in H3 uptake between Neo, MUC1 and Y0 at varying 
concentrations of the drugs is shown as p-values (n=4) (**p<0.01, *** p<0.001). (b) RT-
PCR data showing fold changes in the m-RNA level of MDR genes that are associated 
with multidrug resistance. (c) ChIP– CR assay reveals an interaction between full length 
MUC1 CT and MUC1 YO with the promoter region of the ABCC1 gene. ChIP–PCR; 
lanes include: Input DNA, DNA precipitated using control IgG and CT2, and amplified 
by PCR using Taq polymerase and separated by 2% agarose gel. 
 
 
 
 
 
 
(a) 
(b) 
(c) 
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APPENDIX A: FIGURE 
 
 
Figure1: MUC1 ELISA showing levels of MUC1 in the serum of PCpatients at 
different stages of the disease. 
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APPENDIX B: DENSITOMETRIC ANALYSIS 
Supplemental Table 1. Densitometric analysis of MUC1 and β-actin levels in 
MUC1 siRNA treated Capan-1 cell line using Image J software (Figure 1C). 
Samples MUC1 β-actin 
  Area Mean Adjusted 
mean 
Area Mean Adjusted 
mean 
Capan-1 WT 0.08 35.09 35.09 0.03 119.16 1.00 
Capan-1 Ctrl siRNA 0.08 40.10 46.26 0.03 103.31 1.15 
Capan-1 MUC1 siRNA 0.08 3.63 3.66 0.03 118.16 1.01 
% expression after 
knockdown 
  10.43    
 
Supplemental Table 2. Densitometric analysis of MUC1 and β-actin levels 
in KCKO and KCM cell lines using Image J software (Figure 2A). 
Samples MUC1 β-actin 
  Area Mean Adjusted 
mean 
Area Mean Adjusted 
mean 
KCKO 0.11 15.36 19.40 0.02 98.10 1.26 
KCM 0.11 141.88 141.88 0.02 123.94 1.00 
 
Supplemental Table 3. Densitometric analysis of MUC1 and β-actin levels 
in BxPC3 Neo and BxPC3 MUC1 cell lines using Image J software (Figure 
3A). 
Samples MUC1 β-actin 
  Area Mean Adjusted 
mean 
Area Mean Adjusted 
mean 
BxPC3 Neo 0.11 0.00 0.00 0.04 119.80 1.1 
BxPC3 
MUC1 
0.11 97.01 97.01 0.04 129.61 1.0 
 
Supplemental Table 4. Densitometric analysis of MRP1 and  β-actin levels 
in BxPC3 Neo and BxPC3 MUC1  tumor lysate using Image J software  
(Figure 4B). 
Samples MRP1 β-actin 
  Area Mean Adjusted 
mean 
Area Mean Adjusted 
mean 
KCKO 0.08 42.01 42.01 0.06 110.39 1.00 
KCM 0.08 124.33 125.39 0.06 109.46 1.01 
BxPC3 Neo 0.09 54.00 58.96 0.06 96.57 1.09 
BxPC3 
MUC1 
0.09 144.24 144.24 0.06 105.44 1.00 
 
138 
 
Supplemental Table 5. Densitometric analysis of MUC1 expression in BxPC3 Neo and BxPC3 MUC1  tumor 
lysate using Image J software  (Figure 4D). 
Samples MUC1 MRP1 β-actin 
 Area Mean Adjusted 
mean 
Area Mean Adjusted 
mean 
Area Mean Adjusted 
mean 
BxPC3 Neo  sample 
#1 
0.224 62.521 76.3 0.061 80.36 98.07 0.061 127.1 1.22 
BxPC3 Neo  sample 
#2 
0.224 70.731 73.2 0.061 81.45 84.26 0.061 149.9 1.03 
BxPC3 MUC1  sample 
#4 
0.224 141.456 141.5 0.061 99.34 99.34 0.061 155.1 1.00 
 
Supplemental Table 6. Densitometric analysis of phospho Akt and total Akt levels in cell lines using image J 
software (Figure 5A). 
 
Sampl
es 
phospho-Akt Akt β-actin  MUC1+
ve/MUC
1 -ve 
 Area Mean Adjust
ed 
mean 
Area Mean Adjus
ted 
mean 
Area Mean Adjus
ted 
mean 
phospho 
Akt/tota
l Akt 
phospho 
Akt/total 
Akt 
KCKO 0.03 66.8 70.2 0.0 117.9 124.0 0.0 158.3 1.1 0.6     
KCM 0.03 120.5 120.5 0.0 113.2 113.2 0.0 166.4 1.0 1.1 1.9 
BxPC3 
Neo 
0.04 72.5 77.3 0.0 145.2 154.8 0.0 141.6 1.1 0.5     
BxPC3 
MUC1 
0.04 154.0 156.8 0.0 164.3 167.3 0.0 148.3 1.0 0.9 1.9 
Supplemental Table 7. Densitometric analysis of total Akt, MRP1, MUC1 and β-actin levels in Akt siRNA 
treated Capan-1 cells using image J software (Figure 5 B). 
Samples Akt MRP1 MUC1  β-actin  
  Mean Adjusted 
mean 
Mean Adjusted 
mean 
Mean Adjusted 
mean 
Mean Adjusted 
mean 
          
Capan-1 WT 131.4 131.4 194.8 194.8 75.7 75.7 161.1 1.0 
Capan-1 Ctrl siRNA 133.6 139.5 100.4 104.9 65.0 67.9 154.3 1.0 
Capan-1 Akt siRNA 94.3 80.1 35.6 35.9 23.4 23.5 160.1 1.0 
% expression after 
kncokdown 
 61.0       
Fold change    5.4  3.2   
 
Supplemental Table 8. Densitometric analysis of total Akt, MRP1, MUC1 and β-actin levels in Akt siRNA 
treated BxPC3 cells using image J  (Figure 5 C). 
Samples Akt MRP1 MUC1 β-actin 
  Mean Adjuste
d mean 
Mean Adjuste
d mean 
Mean Adjuste
d mean 
Mean Adjuste
d mean 
BxPC3 Neo WT 149.0 166.4 83.943 93.7 4.998 5.6 90.157 1.1 
BxPC3 MUC1 WT 125.6 176.5 137.408 193.1 124.328 174.7 71.64 1.4 
BxPC3 MUC1 Ctrl 
siRNA 
114.2 139.9 112.779 138.2 87.616 107.4 82.154 1.2 
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BxPC3 MUC1 Akt 
siRNA 
86.5 86.5 41.376 41.4 71.432 71.4 100.667 1.0 
% expression after 
kncokdown 
 49.02       
Fold change    4.67  2.45   
 
Supplemental Table 9. Densitometric analysis of total Akt, MRP1, MUC1 and β-actin levels in KCKO cells and 
Akt siRNA treated KCM cells using image J  (Figure 5D). 
Samples Akt MRP1 MUC1 β-actin 
  Mean Adjuste
d mean 
Mean Adjuste
d mean 
Mean Adjuste
d mean 
Mean Adjuste
d mean 
KCKO WT 93.9 117.3 56.9 71.0 0.0 0.0 82.5 1.2 
KCM WT 79.2 81.4 93.6 96.3 132.1 135.8 100.3 1.0 
KCM Ctrl siRNA 80.2 89.0 84.8 94.1 135.6 150.5 92.9 1.1 
KCM Akt siRNA 22.9 22.9 81.6 81.6 115.9 115.9 103.1 1.0 
% expression after 
kncokdown 
 28.159       
Fold change    1.18  1.17   
 
 
 
Supplemental Table 10. Densitometric analysis of the PCR 
product following ChIP assay in Capan-1 cells  (Figure 6C). 
ChIP region I Area Arbitary 
units 
Fold enrichment 
(CT2 DNA/ IgG 
DNA) 
Capan-1 Input 5472 242  
Capan-1 IgG 5472 19  
Capan-1 CT2 5472 124 6.5 
ChIP region II Area Arbitary 
units 
Fold enrichment 
(CT2 DNA/ IgG 
DNA) 
Capan-1 Input 4300 240  
Capan-1 IgG 4300 46    
Capan-1 CT2 4300 16 0.3 
 
Supplemental Table 11. Densitometric analysis of the 
PCR product following ChIP assay in KCKO and KCM 
cells  (Figure 6C). 
ChIP region I Area Arbitary 
units 
Fold enrichment 
(CT2 DNA/ IgG 
DNA) 
KCKO Input 840 185  
KCKO IgG 840 43  
KCKO CT2 840 29 0.7 
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KCM Input 0.11 152  
KCM IgG 0.11 40  
KCM CT2 0.11 128 3.2 
ChIP region 
II 
Area Arbitary 
units 
Fold enrichment 
(CT2 DNA/ IgG 
DNA) 
KCKO Input 406 85  
KCKO IgG 406 27  
KCKO CT2 406 20 0.7 
KCM Input 0.08 141  
KCM IgG 0.08 35  
KCM CT2 0.08 25 0.7 
 
Supplemental Table 12. Densitometric analysis of the 
PCR product following ChIP assay in BxPC3 Neo and 
BxPC3 MUC1 cells  (Figure 6C). 
ChIP region I Area Arbitary 
units 
Fold enrichment 
(CT2 DNA/ IgG 
DNA) 
BxPC3 Input 0.03 123.3  
BxPC3 IgG 0.03 96.1  
BxPC3 CT2 0.03 108.4 1.1 
BxPC3 Input 0.03 212.6  
BxPC3 IgG 0.03 93.3  
BxPC3 CT2 0.03 101.7 1.1 
ChIP region II Area Arbitary 
units 
Fold enrichment 
(Chip/Input DNA) 
BxPC3 Input 0.03 95.1  
BxPC3 IgG 0.03 83.9  
BxPC3 CT2 0.03 85.3 1.0 
BxPC3 Input 0.03 98.6  
BxPC3 IgG 0.03 80.5  
BxPC3 CT2 0.03 79.7 1.0 
 
Supplemental table 13: Densitomectric analysis of figure 3.9B. Cox-2 expression following MUC1 overexpression 
in BxPC3 and Panc02 cells and MUC1 knockdown in KCKO cells. 
 MUC1 Cox-2 b-actin 
 Area Mean Adjusted 
mean 
Area Mean Adjusted 
mean 
Area Mean Adjusted 
mean 
BxPC3 Neo 0.1 2.9 2.9 0.1 27.4 27.4 0.0 85.6 1.0 
BxPC3 MUC1 0.1 87.5 90.4 0.1 87.4 90.3 0.0 82.8 1.0 
Fold increase   31.0   3.3    
Panc02 Neo 0.1 15.3 19.1 0.0 21.9 27.4 0.0 95.9 1.2 
Panc02 MUC1 0.1 91.8 91.8 0.0 71.5 71.5 0.0 119.7 1.0 
Fold increase   4.8   2.6    
KCKO 0.1 5.2 8.6 0.0 11.5 19.3 0.0 57.1 1.7 
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KCM 0.1 88.3 88.3 0.0 74.4 74.4 0.0 95.4 1.0 
Fold increase   10.2   3.9    
 
Supplemental table 14: Densitomectric analysis of figure 3.9C. Cox-2 expression following MUC1 knockdown in 
HPAFII and HPAC cells 
 MUC1 Cox-2 b-actin 
 Area Mean Adjuste
d mean 
Area Mean Adjusted 
mean 
Area Mean Adjuste
d mean 
HPAFII WT 0.1 106.3 116.4 0.0 60.2 65.9 0.1 103.4 1.1 
HPAFII Ctrl siRNA 0.1 100.3 128.2 0.0 64.0 81.8 0.1 88.6 1.3 
HPAFII MUC1 siRNA 0.1 10.7 10.7 0.0 18.9 18.8 0.1 113.2 1.0 
Fold decrease   10.9   3.5    
HPAC WT 0.1 121.0 121.0 0.0 76.4 76.4 0.1 107.3 1.0 
HPAC Ctrl siRNA 0.1 98.3 102.0 0.0 72.6 75.4 0.1 103.4 1.0 
HPAC MUC1 siRNA 0.1 19.3 20.7 0.0 12.2 13.1 0.1 99.8 1.1 
Fold decrease   5.8   5.8    
 
Supplemental table 15: Densitometric analysis of figure 3.10 A. Level of Cox-2 
mRNA evaluated by semi-quantitative RT-PCR. 
 Cox-2 mRNA GAPDH2/Gapdh2 
Cell Lines Area Mean Adjusted 
mean 
Area Mean Adjusted 
mean 
BxPC3 Neo 0.02 125.6 143.1 0.02 112.6 1.1 
BxPC3 MUC1 0.02 135.2 135.2 0.02 128.2 1.0 
Fold difference   1.06    
Panc02 Neo 0.021 151.7 160.96 0.025 205.1 1.1 
Panc02 MUC1 0.021 189.2 189.21 0.025 217.6 1.0 
Fold difference   1.2    
KCKO 1326 92.08 119.38 1030 154.4 1.30 
KCM 1326 178.9 178.93 1030 200.2 1.00 
Fold difference   1.5    
HPAF WT 0.085 197.9 204.1 0.147 206.1 1.0 
HPAC Ctrl siRNA 0.085 235.3 235.3 0.147 212.6 1.0 
HPAC MUC1 siRNA 0.085 12.35 14.7 0.147 178.8 1.2 
Fold difference   13.9    
 
Supplemental table 16: Densitometric analysis of figure 3.11A. Nuclear localization of MUC1 CT and NF-kB in 
cells. 
 NFkB MUC1 CT Lamin A/c 
Cell Lines Area Mean Adjusted 
mean 
Area Mean Adjusted 
mean 
Area Mean Adjusted 
mean 
Panc02 Neo 0.03 78.9 78.8 0.14 0.1 0.1 0.1 43.0 1.0 
Panc02 MUC1 0.03 55.8 68.6 0.14 121.4 149.2 0.1 35.0 1.2 
Fold difference   1.1   1254    
KCKO 0.024 222.2 222.2 0.14 2.1 2.1 0.155 63.572 1.0 
KCM 0.024 170.8 234.7 0.14 69.9 96.1 0.155 46.262 1.4 
Fold difference   0.9   45.4    
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Supplemental table 17: Densitometric analysis of figure 
3.11C. ChIP data 
Cell Lines Area Mean Fold 
enrichment 
Panc02 Neo Input 0.04 107  
Panc02 Neo IgG 0.04 0  
Panc02 Neo CT2 0.04 0  
Panc02 Neo NF-kB 0.04 1  
Panc02 MUC1 Input 0.04 177.4  
Panc02 MUC1 IgG 0.04 0  
Panc02 MUC1 CT2 0.04 97.8  
Panc02 MUC1 NF-kB 0.04 59.6  
KCKO Input 1290 197.3  
KCKO IgG 1290 1.527  
KCKO CT2 1290 0.626  
KCKO NF-kB 1290 0.153  
KCM Input 0.243 176.4  
KCM IgG 0.243 18.52  
KCM CT2 0.243 135.9 7.34 
KCM NF-kB 0.243 109.6 5.92 
HPAFII Input 1672 191.5  
HPAFII IgG 1672 57.01  
HPAFII CT2 1672 125.6 2.2 
HPAFII NFkB 1672 129.8 2.3 
 
 
 
 
 
 
 
